

Published in final edited form as:


J Org Chem. 2008 November 21; 73(22): 8901–8920. doi:10.1021/jo801312r.

The Design, Synthesis and Evaluation of Coumarin Ring Derivatives of the Novobiocin Scaffold that Exhibit Anti-proliferative Activity

Alison C. Donnelly^{†,1}, Jared R. Mays^{†,1}, Joseph A. Burlison[†], John T. Nelson[†], George Vielhauer[‡], Jeffrey Holzbeierlein[‡], and Brian S. J. Blagg^{*,†}

Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, Kansas 66045-7563, and Department of Urology, The University of Kansas Medical Center, 3901 Rainbow Blvd., Mail Stop 3016, Kansas City, Kansas 66160

Abstract



Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site located on the C-terminus of Hsp90 and induces degradation of Hsp90-dependent client proteins at ~700 μM in breast cancer cells (SkBr3). Although many analogues of novobiocin have been synthesized, it was only recently demonstrated that monomeric species can exhibit anti-proliferative activity against various cancer cell lines. To further refine the essential elements of the coumarin core, a series of modified coumarin derivatives was synthesized and evaluated for elucidation of structure–activity relationships for novobiocin as an anti-cancer agent. Results obtained from these studies have produced novobiocin analogues that manifest low micromolar activity against several cancer cell lines.

Introduction

Increasing resistance to chemotherapeutics and knowledge that cancers employ multiple abnormalities have resulted in an increased interest to target the Hsp90 molecular chaperone for the treatment of cancer.¹ Hsp90 is a molecular chaperone that is responsible for the folding and conformational maintenance of more than 100 Hsp90-dependent client proteins.^{2,3} *In vivo*, Hsp90 substrates have been implicated in cellular signaling networks such as those mediated by steroid hormone receptors, transcription factors and protein kinases, many of which represent individually sought-after anti-tumor targets.^{4–9} Because Hsp90 plays a unique role in regulating the function and stability of a growing number of proteins upon which cancer

*Author to whom correspondence should be addressed. Phone: (785) 864-2288. Fax: (785) 864-5326. Email: bblagg@ku.edu.

[†]The University of Kansas

[‡]The University of Kansas Medical Center

¹Both authors contributed equally to this work

cells depend for survival, as well as many mutated and overexpressed proteins that contribute to cancer cell proliferation, Hsp90 has evolved into a promising drug target.¹⁰

Hsp90 inhibition results in the destabilization of a substrate-bound heteroprotein complex, which in turn, leads to degradation of Hsp90-dependent clients via ubiquitination of the unfolded client followed by proteasome-mediated hydrolysis.^{11–16} As such, small molecule inhibitors of Hsp90 transform the protein folding machinery into a catalyst for protein degradation.¹⁷ Through Hsp90 inhibition, depletion of multiple oncogenic proteins readily occurs and the outcome is similar to a combinatorial attack on multiple signaling nodes that contribute to oncogenic signaling and modulation of the malignant phenotype.^{1,18,19} Hsp90 has been shown to be overexpressed in a wide variety of human malignancies and provides an opportunity for high differential selectivity.^{1,18,20} The ability to simultaneously disrupt multiple signaling events through a single target makes Hsp90 an attractive protein for the development of chemotherapeutic agents.^{1,19,21}

Novobiocin (Figure 1), a member of the coumermycin family of antibiotics, binds to the ATP-binding pocket of DNA gyrase and elicits antimicrobial activity through inhibition of ATP-hydrolysis.^{22–25} Co-crystal structures of GyrB, the B subunit of DNA gyrase, bound to novobiocin and ADP revealed both molecules bind in a bent conformation,^{26–28} similar to the manner in which Hsp90 binds ADP.²⁹ With prior knowledge that novobiocin manifests cytotoxicity and binds to a similarly shaped pocket in DNA Gyrase,^{25,30–33} Neckers and co-workers demonstrated that novobiocin also binds Hsp90 and exhibits anti-tumor activity (~700 μ M) against human breast cancer cells. In testing their hypothesis, Neckers and coworkers showed via Western blot analyses of SKBr3 cell lysates that novobiocin induces degradation of Hsp90-dependent clients in a concentration-dependent manner. Related studies in which truncated variants of Hsp90 were eluted from an immobilized novobiocin solid-support revealed that only the C-terminus of Hsp90 was capable of binding novobiocin, which is in contrast to other Hsp90 inhibitors that bind solely to the well-established N-terminal ATP-binding site.³⁴

In addition, it was found that inhibitors bound to the Hsp90 N-terminus were readily displaced by occupation of the C-terminus by novobiocin, which is not reciprocal.^{34,35} It has been proposed that novobiocin may antagonize Hsp90 function by inducing a conformational change that results in separation of the homodimeric C-terminal domains and subsequent release of substrate³⁶, however studies with improved analogues are needed to confirm this hypothesis. It is proposed that the synthesis of improved analogues will not only allow elucidation of the Hsp90 C-terminal nucleotide-binding pocket, but will also provide insight into the unique mechanism exhibited by Hsp90 during the complex protein folding process.³⁶

Several groups have attempted to develop improved analogues of novobiocin in order to improve its comparatively poor Hsp90 inhibitory activity.³⁴ A library of novobiocin analogues disclosed in 2005 demonstrated that **A4** (Figure 2) induced degradation of Hsp90-dependent client proteins at ~70-fold lower concentration than novobiocin.¹¹ The structure of **A4** included a shortened N-acyl side chain, removal of the 4-hydroxy substituent and an absent carbamoyl group on the noviose appendage. More importantly, this study highlighted that attachment of the noviose moiety to the 7-position and an amide linker at the 3-position of the coumarin ring are critical for anti-Hsp90 activity.¹¹ To confirm the observed SAR trends elucidated from this library, two natural product analogues were prepared and evaluated, **DHN1** and **DHN2** (Figure 2). Upon evaluation of these molecules in several assays, it was confirmed that the 4-hydroxyl and the 3'-carbamate are detrimental to Hsp90 inhibitory activity, but critical for DNA gyrase inhibition.¹⁴

Compound **A4** was found to exhibit unique, previously-undocumented activities. **A4** induced Hsp90 at concentrations 1000–10000-fold lower than that required for client protein degradation and was thus evaluated for neuroprotective activity. **A4** was found to produce an EC₅₀ at 6 nM and exhibited no toxicity at any concentration tested in a model for Alzheimer's disease.¹¹ In contrast to the monomeric species, the **A4-dimer**, based on the structure of coumermycin A1, was found to manifest anti-proliferative activity. These results suggested that modification of the amide side chain resulted in conversion of a nontoxic molecule into an anti-proliferative agent.³⁷ Consequently, a series of monomeric species based on **A4** was synthesized and evaluated for antitumor activity.³⁸ This later study described the synthesis and evaluation of biaryl and heterocyclic amide-derivatives that explore hydrogen-bonding interactions with the putative novobiocin binding pocket that typically binds the prenylated benzamide of the natural product. Eventually these studies led to the first set of SAR for the amide side chain.

Although the Hsp90 C-terminus does not exhibit ATPase activity, it does play a critical role in conformational rearrangement upon ATP binding.³⁶ To further explore SAR, derivatives of **A4** with variations to the coumarin scaffold were designed to probe the importance of interactions typically manifested by the purine ring. These coumarin-derived motifs possess hydrogen bonding capabilities similar to the nucleotide bases, adenine and guanine, and contain strategically placed hydrogen bond acceptors and donors and alkyl groups of variable size to probe the size and nature of the complementary binding pocket. The design, synthesis and evaluation of such compounds are described in this article.

Results and Discussion

Design of new novobiocin analogues

To elucidate structure-activity relationships for the coumarin ring system of novobiocin, we envisioned construction of novobiocin analogues with modified coumarin cores. As shown in Scheme 1, the derivatives were assembled in a modular fashion allowing sequential coupling of noviose and a series of benzoic acids with the modified coumarin cores. We previously demonstrated that the trichloroacetimidate of noviose carbonate couples readily to coumarin phenols in good yield, to afford the corresponding α -anomer.³⁹ The benzoic acids selected were based upon previously obtained SAR for the amide side chain as described by Burlison and co-workers.³⁸

The coumarin scaffolds were designed to complement interactions present on the purine nucleus, via probing the importance of hydrogen bond donor and acceptors in positions surrounding the aromatic ring system. Rationale for these analogues is based on the identification of additional interactions with the nucleotide-binding domain that typically binds the corresponding purine substrate and may lead to enhanced inhibitory affinity for these compounds. Minor perturbations were made on each analogue; however, the addition of one hydrogen bond can produce 1–2 kcal/mol of binding energy and thus increase binding by 10 fold.⁴⁰ Therefore, these complementary interactions can exhibit a substantial impact on binding and subsequent inhibition. While it has been demonstrated that the N-terminal site is fairly specific for adenine nucleotides, the C-terminal site has been shown to be more promiscuous, and binds both purines and pyrimidines. While adenine specifically binds to the N-terminus, GTP and UTP are specific C-terminal substrates.⁴¹ Based on these previous studies, mimics of the guanosine nucleus were chosen to take advantage of this differential. Hydrogen-bond acceptors were placed at the 5-, 6- and 8-positions of the coumarin ring to mimic those at the 6-, 7- and 3-positions of guanine, respectively (Figure 3). Additionally, analogues bearing modification to the coumarin lactone were constructed to probe the importance of hydrogen bond donors/acceptors as well as to potentially improve upon the

solubility of the novobiocin scaffold. The activity of such compounds is likely to provide insight into the interactions that are essential or those that can be further optimized.

There is limited knowledge regarding the shape and dimension of the pocket since the discovery of the C-terminal binding site is a recent achievement and no Hsp90 co-crystal structure bound to C-terminal inhibitors exists. Therefore, several analogues were designed to probe the breadth of the pocket at positions that potentially project into hydrophobic regions. Alkyl and aryl groups of variable size were attached at the 5-, 6- and 8-positions of the coumarin ring to maximize putative hydrophobic interactions and to optimize affinity. A methoxy group was attached at the 5-position of the coumarin ring, while methoxy, propoxy, and isopropoxy ethers were installed at the 6-position. Methyl, methoxy, benzyl and phenyl substituents were placed at the 8-position, offering a variety of possible interactions to fill the pocket that is occupied by the chlorine of chlorobiocin and the methyl substituent of novobiocin. The culmination of structure–activity relationships elucidated by such compounds is likely to provide a platform upon which improved analogues can be sought.

Syntheses of 5-, 6-, and 8-alkyl(oxy) novobiocin analogues

To generate the resorcinol precursors with substitutions at the 4-position, which result in coumarin ring systems with appendages at the 6-position, the phenols of benzaldehyde **1** were protected as the corresponding ethers (Scheme 2). The resulting benzaldehydes (**2a–b**)⁴² were converted to their formate esters via Baeyer-Villiger oxidation, and then hydrolyzed to afford phenols **3a–b**.^{43,44} *O*-Alkylation with the requisite alkyl iodide proceeded in good yield and generated a series of protected 4-substituted resorcinolic ethers (**4a–c**). *Ortho*-lithiation of **4a–c**, followed by alkylation with methyl iodide provided the 2-methyl protected resorcinols, **5a–c**.⁴⁵ Deprotection⁴⁶ of the alkoxy ethers by exposure to acidic conditions gave resorcinols **6a–c**.

To generate resorcinol precursors with substitutions at the 5-position, the phenols of 5-methoxy resorcinol **7** were once again protected as the corresponding alkoxy ethers, **8** (Scheme 3). *Ortho*-lithiation of **8**, followed by treatment with methyl iodide, led to installation of a methyl group at the 2-position of **9**.⁴⁵ Acidic deprotection⁴⁶ was employed to afford resorcinol **10**.

To generate the resorcinol precursors with aryl substituents at the 2-position, the phenols of resorcinol **11** were protected as the corresponding alkoxy ethers, **12** (Scheme 4). Subsequent *ortho*-lithiation of **12**, followed by the addition of benzyl bromide provided the benzyl derivative, **13**.⁴⁵ Removal of the ether protecting groups⁴⁶ gave diphenol **14**.⁴⁵ The anion of resorcinol **12** was also employed to construct the corresponding 2-iodide via reaction with iodine to yield **15**.⁴⁷ A Suzuki coupling in the presence of biaryl ligand S-Phos,⁴⁸ was used to generate biaryl **16**, which underwent deprotection⁴⁶ to provide **17**.

To generate resorcinol precursors with alkyl substitutions at the 2-position, pyragallol (**18**) was *O*-alkylated with methyl iodide to generate 2-methoxy resorcinol amongst an inseparable mixture of regioisomers (Scheme 5). The mixture was subsequently subjected to coumarin formation and the corresponding products isolated. Preparation of 2-ethyl resorcinol (**21**) from 2,6-dihydroxyacetophenone (**20**) was accomplished according to published procedures.⁴⁹

Once resorcinols **6a–c**, **10**, **14**, **17**, **19**, and **21** were obtained, the corresponding coumarins **23a–h** were synthesized through a modified Pechmann condensation with enamine **22** as previously described.^{50,51} The resulting coumarin phenols were noviosylated with the trichloroacetimidate of noviose cyclic carbonate (**24**) in the presence of catalytic boron trifluoride etherate to generate scaffolds **25a–h** in good yield.³⁹ The benzyl carbonate was removed via hydrogenolysis to produce the aminocoumarin, which was readily coupled with preselected benzoic acids in the presence of *N*-(3-dimethylamino-propyl)-*N'*-

ethylcarbodiimide hydrochloride (EDCI) and pyridine. Benzoic acids were chosen based on previously determined SAR trends reported by Burlison and co-workers.³⁸ The cyclic carbonates were treated with triethylamine in methanol to give the solvolized products, **26a–p** in moderate to good yield over three steps.

Syntheses of quinoline- and naphthalene-containing novobiocin analogues

Novobiocin analogues containing a quinoline or naphthalene ring in lieu of the 8-methylcoumarin of novobiocin were synthesized to probe the importance of the coumarin lactone moiety in binding the Hsp90 C-terminus, as well as to potentially circumvent the limited solubility of coumarin-containing analogues. Protection of the phenol in **27** as the *t*-butyl-carbonate⁵² served two purposes (Scheme 7). Not only did phenol protection remove the quinolone-like properties of **27**, introduction of the sterically-hindered *t*-butyl-carbonate also decreased the relative amount of 6- and 8-bromo regioisomers normally produced upon bromination of **28**. Thus, the isolable percentage of desired 3-bromo regioisomer was enriched to 46% yield.⁵³ One-pot *t*-butyl-carbonate deprotection, followed by immediate reprotection with benzyl bromide afforded intermediate **30**. *N*-arylation of **30** was accomplished with *p*-methoxybenzylamine under Ullman-like conditions employing CuI and L-(–)-proline as a catalyst to provide **31**.⁵⁴ Acylation of the secondary aniline with the desired benzoyl chloride,⁵⁵ generated *in situ* from the appropriate benzoic acid,⁵⁶ afforded PMB-protected amide **32**. Interestingly, subjection of **32** to aluminum trichloride in anisole⁵⁷ resulted solely in the formation of 7-hydroxy **33**; the PMB-protected amide remained intact. Global removal of the PMB and benzyl groups was ultimately accomplished with trifluoroacetic acid, to provide phenol **34**.⁵⁸


Construction of the corresponding naphthalene-containing analogues began by benzyl protection of phenol **35**, to provide **36** in high yield (Scheme 8).⁵⁹ *N*-arylation of **36** with *p*-methoxybenzylamine provided **37**.⁵⁴ which was acylated with the desired benzoyl chloride to afford **38**.^{55,56} 6-Benzyloxy deprotection of **38** to **39** was performed with aluminum trichloride in anisole,⁵⁷ while concurrent benzyl- and PMB-deprotection to intermediate **40** was accomplished with trifluoroacetic acid.⁵⁸

Phenols **33**, **34**, **39**, and **40** were noviosylated with the trichloroacetimide of noviose carbonate (**24**) in the presence of boron trifluoride etherate to provide noviose carbonate analogues **41a–d**.³⁹ In particular, analogues **33** and **34** containing the quinoline nitrogen were both slow to react and low yielding, even when greater than stoichiometric boron trifluoride etherate was employed, suggesting chelation of the quinoline nitrogen to boron was problematic. Solvolysis of carbonates **41a–d** with triethylamine in methanol/dichloromethane afforded diols **42a–d** in moderate yields.

Biological evaluation of novobiocin analogues


Upon construction of the library of novobiocin analogues, the compounds were evaluated for anti-proliferative activity against SkBr3 (estrogen receptor negative, Her2 over-expressing breast cancer cells), MCF-7 (estrogen receptor positive breast cancer cells), LnCaP (androgen receptor sensitive prostate cancer cells) and PC-3 (androgen receptor insensitive prostate cancer cells) cell lines. As shown in Table 1, the 6-substituted analogues containing the biaryl sidechain (**26a–26c**) were 3- to 7-fold less active against the two breast cancer cells than analogues containing hydrogen at this position.³⁸ These analogues were more active against prostate cancer cells than breast cancer cells versus the corresponding 6-H derivative. For reasons that remain unclear, the putative binding pocket for biaryl-containing analogues does not appear to tolerate incorporation of steric bulk at the 6-position. Analogues containing the 2-indole sidechain (**26i–26k**) were consistently more active than their corresponding biaryl derivatives, in-line with previously-observed trends.³⁸ Analogue **26j**, containing a 6-propoxy-

coumarin, was consistently the most potent derivative in this library exhibiting 2-fold enhanced potency relative to its 6-H analogue against LnCaP cells.



By comparison, incorporation of a hydrogen-bond acceptor at the 5-position (**26d**, **26l**) resulted in equivalent or decreased activity versus corresponding 6-H analogues, especially against both breast cancer cell lines.³⁸ In general, 5-methoxy functionalized coumarins do not appear beneficial for anti-proliferative activity.

It was previously demonstrated that 8-methyl analogues were ~10-fold more active than the corresponding 8-hydrogen derivatives.³⁸ To further elaborate upon this trend, a larger selection of 8-functionalized coumarins were evaluated. Incorporation of an 8-methoxy (**26g**) led to 2-fold improved activity over its 8-methyl counterpart, and 5-fold increased activity over the similarly-sized 8-ethyl derivative **26h**. Introduction of steric bulk (**26e**, **26f**) generally decreased anti-proliferative activity, especially against MCF-7 cells. It appears that while short alkoxy side chains take advantage of putative interactions, steric bulk appears detrimental to inhibitory activity at this location. A similar trend was observed against prostate cancer cells, with **26g** and **26h** exhibiting 10-fold increased activity versus their 8-methyl counterparts.³⁸ Surprisingly, 8-benzyl **26e** was more than twice as active as the 8-methyl derivative against LnCaP cells. In contrast, 8-position analogues containing the 2-indole sidechain (**26m**–**26p**) did not exhibit similar, consistent trends against prostate and breast cancer cells. Against breast cancer cells, compounds **26m**, **26n**, and **26p** exhibited significantly reduced activity versus the 8-methyl derivative. The 8-methoxy **26o** was inactive against MCF-7 cells, while both **26o** and **26p** were inactive against both PC-3 and LnCaP cells. The selectivity of **26o** and **26p** for breast cancer cells versus prostate cancer cells is intriguing and requires further investigation.



As shown in Table 2, compounds **42a** and **42c** containing the *p*-MeOBn-alkylated amides did not exhibit anti-proliferative activity against the cell lines tested. This is in contrast to analogues **42b** and **42d** lacking the *p*-MeOBn functionality, which manifested modest antiproliferative activity. This stark difference suggests one of two scenarios regarding the role of the *p*-MeOBn functionality; either the *p*-MeOBn group of tertiary amides **42a** and **42c** is unable to occupy the same pocket as the 4-aryloxy substituted novobiocin analogues^{60,61} or more simply, the secondary amide is required for benzamide-containing novobiocin analogues to manifest anti-proliferative activity, an observation consistent with prior structure–activity trends.³⁸ It is plausible that the steric congestion of amides **42a** and **42c** forces adoption of a more static conformation that disallows *cis/trans* isomerization of the amide, a feature that has been hypothesized to be essential for anti-proliferative activity of novobiocin analogues against bacteria. Further evidence was gathered upon realization that the lack of reactivity for tertiary

amides **42a** and **42c** to all but the harshest conditions for *p*-MeOBn removal^{58,62,63} suggest these compounds may adopt a highly-organized and stable conformation.

Against breast cancer cells, analogue **42b** exhibited similar anti-proliferative activities as the corresponding 8-methylcoumarin analogue, while **42d** was between 2- and 5-fold less active.³⁸ In contrast, both **42b** and **42d** were significantly more active against PC-3 cells than the corresponding 8-methylcoumarin; **42b** and **42d** exhibited between 7- to 9-fold reduced activity against LnCap cells. Given that both **42b** and **42d** lack the 8-methyl feature that yields an increased activity of ~10-fold, it is reasonable to hypothesize that the quinoline- and naphthalene-derived analogues that include an 8-methyl substituent could exhibit anti-proliferative activities between 1–5 μM against breast cancer cells and 1–2 μM against prostate cancer cells, approximately an order of magnitude less than the novobiocin analogue containing a coumarin. These results suggest that, while the lactone moiety may provide beneficial hydrogen-bonding interactions with the novobiocin binding pocket, these interactions may not be required to manifest anti-proliferative activity. More importantly, these results implicate that continued optimization of the coumarin scaffold connecting the sugar and benzamide motifs is likely to produce compounds with enhanced anti-proliferative activity. A summary of the observed trends for anti-proliferative activities of coumarin-derived novobiocin analogues is depicted in Figure 4.

To provide additional support that the anti-proliferative activities exhibited by coumarin-derived novobiocin analogues results from Hsp90 inhibition, analogues **26g**, **26j**, and **42d** were evaluated for their abilities to induce degradation of Hsp90-dependent client proteins. As shown in Figure 5, the Hsp90 client proteins Her2 and Raf were degraded in MCF-7 cells in a concentration-dependent manner upon treatment with coumarin-derived novobiocin analogs. Moreover, Hsp90 client protein degradation correlates well with observed anti-proliferative IC₅₀s; **26g** (IC₅₀ = 9.0 μM) and **26j** (IC₅₀ = 2.1 μM) induced client degradation at ~10 μM , while **42d**, with its more modest anti-proliferative activity (IC₅₀ = 46.4 μM), induced client degradation at ~50 μM . Since actin, a non-Hsp90-dependent protein, is not affected by these analogues, anti-proliferative activities of these analogues correlate directly with Hsp90-client protein degradation.

Conclusions

Compound **26g** and **26j** demonstrated the most potent anti-proliferative activity against the cancer cell lines tested and represent scaffolds that will be further probed to improve activity. Derivatives **26f** and **26o** appear to represent compounds that exhibit differential selectivity for one cancer cell lines versus another, for reasons that remain unclear. Since these compounds demonstrated low micromolar activity against one cell line and are inactive against others, they may provide a tool for further exploration and perhaps unraveling of the complicated processes affected. The activities of analogues **42b** and **42d**, the first documented novobiocin analogues lacking the coumarin functionality, implicate that, while the coumarin ring may participate in hydrogen bonding interactions with Hsp90 that abrogate activity, these interactions are not essential for anti-proliferation activity through inhibition of Hsp90. These analogues provide sufficient evidence to continue the search for optimal ring systems that bridge the benzamide and noviose functionalities. Studies to construct analogues based upon these structure–activity relationships are currently underway and will be reported in due course.

Experimental Section

2,4-Bis(ethoxymethoxy)benzaldehyde (2a)⁴²

N,N-diisopropylethylamine (25.3 mL, 145 mmol) was slowly added to 2,4-dihydroxybenzaldehyde (5.00 g, 36.2 mmol) in anhydrous *N,N*-dimethylformamide (100 mL)

over 5 min at rt. After 30 min, the solution was cooled to 0° C and chloromethyl ethyl ether (14.2 mL, 145 mmol) was added and the mixture warmed to rt over 12 h. The reaction was quenched by the addition of saturated aqueous NH₄Cl solution and extracted with EtOAc (3 × 50 mL). The combined organic fractions were washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 5:1 → 1:1 Hexane:EtOAc) to give **2a** as a brown amorphous solid (9.10 g, 99%): ¹H NMR (CDCl₃, 400 MHz) δ 10.34 (d, *J* = 2.4 Hz, 1H), 7.81 (dd, *J* = 8.7, 2.8 Hz, 1H), 6.89 (t, *J* = 2.5 Hz, 1H), 6.74 (m, 1H), 5.34 (d, *J* = 2.8, 2H), 5.28 (d, *J* = 2.8, 2H), 3.81-3.71 (m, 4H), 1.28-1.22 (m, 6H).

2,4-Bis(ethoxymethoxy)phenol (**3a**)

A solution of **2a** (3.78 g, 12.0 mmol) in anhydrous CH₂Cl₂ (4.0 mL) was slowly added to *m*CPBA (70%) (3.26 g, 13.2 mmol) in anhydrous CH₂Cl₂ (16.3 mL) at 0° C. The resulting solution was warmed to rt, then refluxed for 12 h. After cooling to rt, the resulting solution was washed with saturated aqueous NaHCO₃ solution (3 × 20 mL) and 10% aqueous Na₂S₂O₃ (30 mL). Combined organic fractions were dried (Na₂SO₄), filtered, and concentrated. The residue was re-dissolved in MeOH (5 mL) and stirred with excess 10% aqueous NaOH for 3 h at rt. The pH was adjusted to 2 with 6M HCl and the solution was extracted with CH₂Cl₂ (3 × 10 mL). Combined organic fractions were dried (Na₂SO₄), filtered, and concentrated to give **3a** as an orange oil (8.21 g, 94%): ¹H NMR (CDCl₃, 500 MHz) δ 6.89-6.85 (m, 2H), 6.67 (dd, *J* = 8.8, 2.7 Hz, 1H), 5.81 (d, *J* = 6.6 Hz, 1H), 5.23 (s, 2H), 5.15 (s, 2H), 3.80-3.73 (m, 4H), 1.29-1.24 (m, 6H); ¹³C NMR (CDCl₃, 125 MHz) δ 151.0, 145.0, 141.5, 115.2, 110.6, 106.0, 94.9, 94.2, 64.8, 64.1, 15.1, 15.1; IR (film) ν_{max} 3362, 2887, 1460, 1286, 1162, 735 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + Na]⁺ calcd for C₁₂H₁₈O₅, 265.1052; found, 265.1045.

2,4-Bis(methoxymethoxy)phenol (**3b**)⁴⁴

Benzaldehyde **2b** (700 mg, 3.11 mmol) in CHCl₃ (1.80 mL) at 0° C was treated with *m*CPBA (70% w/w, 1.61 g, 9.33 mmol). After 10 min, the solution was warmed to rt, then refluxed for 12 h. Upon cooling to rt, the solution was washed with saturated aqueous NaHCO₃ (3 × 10 mL), saturated aqueous Na₂SO₃ (20 mL), saturated aqueous NaCl, was dried (Na₂SO₄), filtered, and concentrated. The residue was dissolved in MeOH (5 mL) and stirred with excess triethylamine for 3 h at rt. The solvent was concentrated and the residue purified by column chromatography (SiO₂, 4:1 → 3:1 Hexane:EtOAc) to afford **3b** as a yellow oil (320 mg, 50%): ¹H NMR (CDCl₃, 400 MHz) δ 6.87 (d, *J* = 8.9 Hz, 1H), 6.86 (s, 1H), 6.67 (dd, *J* = 11.5, 2.8 Hz, 1H), 5.21 (s, 2H), 5.11 (s, 2H), 3.54 (s, 3H), 3.50 (s, 3H).

2,4-Bis(ethoxymethoxy)-1-methoxybenzene (**4a**)

Potassium carbonate (14.3 g, 103 mmol) was added to **3a** (2.50 g, 10.3 mmol) in *N,N*-dimethylformamide (103 mL). After 10 min, methyl iodide (6.43 mL, 103 mmol) was added and the solution was heated to reflux for 12 h. Upon cooling to rt, the solution was extracted with EtOAc (3 × 50 mL); combined organic fractions were washed with saturated aqueous NaCl, dried (Na₂SO₄), and concentrated. The residue was purified by column chromatography (SiO₂, 4:1 Hexane:EtOAc) to afford **4a** as a yellow oil (2.40 g, 91%): ¹H NMR (CDCl₃, 500 MHz) δ 6.87 (d, *J* = 2.8 Hz, 1H), 6.72 (d, *J* = 8.9 Hz, 1H), 6.60 (dd, *J* = 13.3, 1.7 Hz, 1H), 5.18 (s, 2H), 5.07 (s, 2H), 3.76 (s, 3H), 3.72-3.69 (m, 2H), 3.68-3.63 (m, 2H), 1.17-1.13 (m, 6H); ¹³C NMR (CDCl₃, 125 MHz) δ 150.7, 146.2, 143.9, 111.2, 107.9, 105.8, 93.2, 93.0, 63.3, 63.0, 55.4, 14.1, 14.0; IR (film) ν_{max} 2976, 2932, 2899, 2835, 1595, 1508, 1393, 1227, 1153, 1103, 1080, 1009, 847 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + Na]⁺ calcd for C₁₃H₂₀O₅, 279.1208; found, 279.1181.

2,4-Bis(methoxymethoxy)-1-propoxybenzene (4b)

Potassium carbonate (322 mg, 2.33 mmol) was added to **3b** (50 mg, 0.233 mmol) in *N,N*-dimethylformamide (2.33 mL) at rt. After 10 min, iodopropane (226 μ L, 2.33 mmol) was added and the solution was heated to reflux for 12 h. Upon cooling to rt, the solution was extracted with EtOAc (3 \times 10 mL); combined organic fractions were washed with saturated aqueous NaCl, dried (Na_2SO_4), filtered, and concentrated. The residue was purified by column chromatography (SiO_2 , 5:1 Hexane:EtOAc) to afford **4b** as a yellow oil (36.4 mg, 61%): ^1H NMR (CD_2Cl_2 , 400 MHz) δ 6.87 (s, 1H), 6.84 (d, $J = 2.9$ Hz, 1H), 6.68 (dd, $J = 11.7, 2.8$ Hz, 1H), 5.19 (s, 2H), 5.12 (s, 2H), 3.93 (t, $J = 6.6$ Hz, 2H), 3.53 (s, 3H), 3.49 (s, 3H), 1.86-1.78 (m, 2H), 1.06 (t, $J = 7.5$ Hz, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 150.6, 146.5, 143.8, 113.7, 108.5, 106.6, 94.7, 94.2, 70.3, 55.2, 54.9, 21.6, 9.5; IR (film) ν_{max} 2961, 2826, 1595, 1506, 1400, 1261, 1154, 1013, 1076, 924, 800 cm^{-1} ; HRMS (ESI^+) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{20}\text{O}_5$, 257.1389; found, 257.1410; $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{13}\text{H}_{20}\text{O}_5$, 279.1208; found, 279.1165.

2,4-Bis(ethoxymethoxy)-1-isopropoxybenzene (4c)

Potassium carbonate (2.85 g, 20.7 mmol) was added to **3a** (500 mg, 2.07 mmol) in *N,N*-dimethylformamide (4.10 mL) at rt. After 10 min, 2-iodopropane (2.06 mL, 20.7 mmol) was added and the solution was heated to reflux for 12 h. Upon cooling to rt, the solution was extracted with EtOAc (3 \times 20 mL); combined organic fractions were washed with saturated aqueous NaCl, dried (Na_2SO_4), filtered, and concentrated. The residue was purified via column chromatography (SiO_2 , 5:1 \rightarrow 1:1 Hexane:EtOAc) to afford **4c** as a yellow oil (0.32 g, 55%): ^1H NMR (CD_2Cl_2 , 400 MHz) δ 6.87 (s, 1H), 6.86 (d, $J = 4.9$ Hz, 1H), 6.66 (dd, $J = 11.6, 3.4$ Hz, 1H), 5.23 (s, 2H), 5.17 (s, 2H), 4.44-4.38 (m, 1H), 3.83-3.72 (m, 4H), 1.33 (s, 3H), 1.31 (s, 3H), 1.27-1.23 (m, 6H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 152.4, 149.1, 143.2, 118.6, 109.5, 107.5, 94.4, 93.9, 72.8, 64.3, 64.1, 22.2 (2C), 15.1, 15.1; IR (film) ν_{max} 2976, 1591, 1504, 1528, 1391, 1258, 1217, 1107, 1011, 847 cm^{-1} ; HRMS (ESI^+) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{24}\text{O}_5$, 285.1702; found, 285.1746; $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{15}\text{H}_{24}\text{O}_5$, 307.1522; found, 307.1310.

1,3-Bis(ethoxymethoxy)-4-methoxy-2-methylbenzene (5a)

A solution of **4a** (632 mg, 2.27 mmol) in anhydrous THF (1.94 mL) was added dropwise to a solution of $^t\text{BuLi}$ (2.5 M in hexanes, 1.48 mL, 3.70 mmol) in anhydrous THF (1.62 mL) at rt. After 1 h, the solution was cooled to -78°C and methyl iodide (620 μ L, 9.87 mmol) was added. The resulting solution was warmed to rt over 12 h, and the reaction was quenched by the addition of saturated aqueous NH_4Cl . Water (5 mL) was added and the solution was extracted with CH_2Cl_2 (3 \times 10 mL). Combined organic fractions were dried (Na_2SO_4), filtered, and concentrated. The residue was purified via column chromatography (SiO_2 , 8:1 \rightarrow 5:1 Hexane:EtOAc) to afford **5a** as a yellow oil (353 mg, 53%): ^1H NMR (CDCl_3 , 500 MHz) δ 6.74 (d, $J = 9.0$ Hz, 1H), 6.60 (d, $J = 9.0$ Hz, 1H), 5.10 (s, 2H), 5.05 (s, 2H), 3.78 (q, $J = 7.1$ Hz, 2H), 3.72 (s, 3H), 3.67 (q, $J = 7.1$ Hz, 2H), 2.14 (s, 3H), 1.18-1.15 (m, 6H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 149.1, 146.5, 121.7, 109.0, 108.4, 96.2, 93.0, 64.3, 63.1, 55.1, 28.7, 14.2, 14.1, 8.8; IR (film) ν_{max} 2918, 2359, 1487, 1260, 1248, 1082, 1055, 945, 798 cm^{-1} ; HRMS (ESI^+) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{14}\text{H}_{22}\text{O}_5$, 293.1365; found, 293.1357.

1,3-Bis(methoxymethoxy)-2-methyl-4-propoxybenzene (5b)

A solution of **4b** (165 mg, 0.64 mmol) in anhydrous THF (520 μ L) was added dropwise to a solution of $^t\text{BuLi}$ (2.5 M in hexanes, 390 μ L, 0.97 mmol) in anhydrous THF (420 μ L) at rt. After 1 h, the solution was cooled to -78°C and methyl iodide (160 μ L, 2.58 mmol) was added. The resulting solution was warmed to rt over 12 h, and the reaction was quenched by the addition of saturated aqueous NH_4Cl . Water (5 mL) was added and the solution was extracted

with CH₂Cl₂ (3 × 10 mL). Combined organic fractions were dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 6:1 Hexane:EtOAc) to afford **5b** as a yellow oil (166 mg, 95%): ¹H NMR (CDCl₃, 500 MHz) δ 6.66 (d, *J* = 9.0 Hz, 1H), 6.60 (d, *J* = 9.0 Hz, 1H), 5.02 (s, 2H), 5.00 (s, 2H), 3.80-3.77 (m, 2H), 3.49 (s, 3H), 3.47 (s, 3H), 2.14 (d, *J* = 7.1 Hz, 3H), 1.73-1.69 (m, 2H), 0.94 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 148.5, 148.5, 147.3, 145.6, 126.7, 123.0, 112.8, 110.8, 110.4, 99.2, 57.7, 57.6, 21.2, 10.9, 10.0; IR (film) ν_{max} 2957, 2924, 2853, 1738, 1597, 1487, 1468, 1391, 1335, 1231, 1157, 974, 798 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₁₄H₂₂O₅, 271.1545; found, 271.1558.

1,3-Bis(ethoxymethoxy)-4-isopropoxy-2-methylbenzene (5c)

A solution of **4c** (190 mg, 0.67 mmol) in anhydrous THF (530 μL) was added dropwise to a solution of ^{*n*}BuLi (2.5 M in hexanes, 410 μL, 1.00 mmol) in anhydrous THF (440 μL) at rt. After 1 h, the solution was cooled to -78° C and methyl iodide (170 μL, 2.67 mmol) was added. The resulting solution was warmed to rt over 12 h, and the reaction was quenched by the addition of saturated aqueous NH₄Cl. Water (5 mL) was added and the solution was extracted with CH₂Cl₂ (3 × 10 mL). Combined organic fractions were dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 6:1 Hexane:EtOAc) to afford **5c** as a yellow oil (157 mg, 79%): ¹H NMR (CDCl₃, 500 MHz) δ 6.70 (d, *J* = 9.0 Hz, 1H), 6.61 (d, *J* = 9.0 Hz, 1H), 5.10 (s, 2H), 5.08 (s, 2H), 4.34 (quintet, *J* = 6.1 Hz, 1H), 3.78 (q, *J* = 7.1 Hz, 2H), 3.67 (q, *J* = 7.1 Hz, 2H), 2.13 (s, 3H), 1.23 (d, *J* = 6.1 Hz, 6H), 1.24-1.15 (m, 6H); ¹³C NMR (CDCl₃, 125 MHz) δ 150.3, 146.6, 145.3, 122.7, 113.7, 110.1, 97.3, 94.0, 71.5, 65.4, 64.2, 29.4, 22.2, 15.2, 15.2, 9.9; IR (film) ν_{max} 2924, 2853, 2359, 2339, 1591, 1483, 1113, 1057, 974 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₁₆H₂₆O₅, 299.1858; found, 299.1909.

4-Methoxy-2-methylbenzene-1,3-diol (6a)

A solution of **5a** (910 mg, 3.37 mmol) in MeOH (28.0 mL) at rt was treated dropwise with 3M HCl (9.00 mL, 26.9 mmol), then heated to reflux for 1 h. Water (30 mL) was added and the solution was extracted with EtOAc (3 × 30 mL). Combined organic fractions were washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 6:1 Hexane:EtOAc) to afford **6a** as a red amorphous solid (509 mg, 98%): ¹H NMR (Acetone-*d*₆, 500 MHz) δ 7.68 (s, 1H), 7.24 (s, 1H), 6.60 (d, *J* = 11 Hz, 1H), 6.29 (d, *J* = 11 Hz, 1H), 3.74 (s, 3H), 2.09 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 144.7, 142.1, 139.7, 115.6, 110.2, 108.6, 55.6, 7.6; IR (film) ν_{max} 3583, 2920, 2359, 1616, 1259, 1090, 1020, 798 cm⁻¹.

2-Methyl-4-propoxybenzene-1,3-diol (6b)

A solution of **5b** (580 mg, 2.15 mmol) in MeOH (17.9 mL) was treated dropwise with 3M HCl (630 μL, 17.2 mmol), then heated to reflux for 1 h. Water (20 mL) was added and the solution was extracted with EtOAc (3 × 20 mL). Combined organic fractions were washed with saturated aqueous NaCl, dried (Na₂SO₄), and concentrated to afford **6b** as a red amorphous solid (387 mg, 99%). ¹H NMR (CDCl₃, 500 MHz) δ 6.51 (d, *J* = 8.7 Hz, 1H), 6.21 (d, *J* = 8.6 Hz, 1H), 5.74 (s, 1H), 4.36 (s, 1H), 3.87-3.85 (m, 2H), 2.09 (s, 3H), 1.75-1.71 (m, 2H), 0.96 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 147.5, 143.8, 139.0, 109.8, 108.4, 103.8, 70.2, 21.6, 9.5, 7.3; IR (film) ν_{max} 3520, 3360, 2966, 2880, 2359, 2341, 1636, 1236, 1068, 785, 750 cm⁻¹.

4-Methoxybenzene-1,3-diol (6c)

A solution of **5c** (157 mg, 0.53 mmol) in MeOH (4.40 mL) at rt was treated dropwise with 3M HCl (1.40 mL, 4.21 mmol), then heated to reflux for 1 h. Water (5 mL) was added and the solution was extracted with EtOAc (3 × 10 mL). Combined organic fractions were washed

with saturated aqueous NaCl, dried (Na₂SO₄), filtered, and concentrated to afford **6c** as a red amorphous solid (95 mg, 99%): ¹H NMR (CDCl₃, 500 MHz) δ 6.54 (d, *J* = 8.7 Hz, 1H), 6.21 (d, *J* = 8.7 Hz, 1H), 5.78 (s, 1H), 4.37-4.32 (m, 1H), 2.09 (s, 3H), 1.25 (d, *J* = 6.1 Hz, 6H); ¹³C NMR (CDCl₃, 125 MHz) δ 147.7, 144.9, 137.5, 110.8, 109.8, 104.0, 71.7, 21.3 (2C); IR (film) ν_{max} 3526, 2974, 2924, 2853, 1717, 1607, 1475, 1238, 1113, 1067, 928, 887, 791 cm⁻¹.

1-Methoxy-3,5-bis(methoxymethoxy)benzene (8)

N,N-diisopropylethylamine (3.15 mL, 18.1 mmol) was added to 5-methoxybenzene-1,3-diol (634 mg, 4.52 mmol) in anhydrous *N,N*-dimethylformamide (12.6 mL) over 5 min at rt. After 30 min, the solution was cooled to 0° C, methoxy methylchloride (3.02 mL, 18.1 mmol) was added, and the solution was warmed to rt over 12 h. The reaction was quenched by the addition of saturated aqueous NaHCO₃ at 0° C and extracted with EtOAc (3 × 10 mL). Combined organic fractions were washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 6:1 → 4:1 Hexane:EtOAc) to afford **8** as a yellow amorphous solid (441 mg, 43%): ¹H NMR (CDCl₃, 500 MHz) δ 6.29 (t, *J* = 2.2 Hz, 1H), 6.21 (d, *J* = 2.2 Hz, 2H), 5.07 (s, 4H), 3.69 (s, 3H), 3.40 (s, 6H); ¹³C NMR (CDCl₃, 125 MHz) δ 161.394, 159.0 (2C), 97.2, 96.2 (2C), 94.5 (2C), 56.1, 55.4 (2C); IR (film) ν_{max} 2997, 2955, 2903, 2827, 1601, 1475, 1400, 1215, 1194, 1146, 1032, 991, 924, 829, 685 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + Na]⁺ calcd for C₁₁H₁₆O₅, 251.0895; found, 251.0910.

5-methoxy-1,3-bis(methoxymethoxy)-2-methylbenzene (9)

A solution of **8** (441 mg, 1.93 mmol) in anhydrous THF (1.55 mL) was added dropwise to a solution of ^tBuLi (2.5 M in hexanes, 1.16 mL, 2.90 mmol) in anhydrous THF (1.26 mL) at rt. After 1 h, the solution was cooled to -78° C and methyl iodide (480 μL, 7.73 mmol) was added. The resulting solution was warmed to rt over 12 h, and the reaction was quenched by the addition of saturated aqueous NH₄Cl. Water (5 mL) was added and the solution was extracted with CH₂Cl₂ (3 × 10 mL). Combined organic fractions were dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 6:1 → 4:1; Hexane:EtOAc) to afford **9** as a yellow oil (314 mg, 67%): ¹H NMR (CDCl₃, 500 MHz) δ 6.38 (d, *J* = 2.2 Hz, 1H), 6.24 (d, *J* = 2.1 Hz, 1H), 5.08 (d, *J* = 3.6 Hz, 2H), 5.06 (d, *J* = 2.6 Hz, 2H), 3.72 (s, 3H), 3.40 (s, 6H), 1.97 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 160.3, 157.8, 155.4, 108.2, 93.9, 93.8, 93.7, 92.9, 55.0, 55.0, 54.6, 7.0; IR (film) ν_{max} 2953, 2934, 2905, 1597, 1497, 1396, 1215, 1144, 1126, 1074, 1059, 1028, 922, 822 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₁₂H₁₈O₅, 243.1233; found, 243.1223.

5-Methoxy-2-methylbenzene-1,3-diol (10)

A solution of **9** (314 mg, 1.30 mmol) in MeOH (10.8 mL) at rt was treated dropwise with 3M HCl (3.46 mL, 10.3 mmol), then heated to reflux for 1 h. Water (11 mL) was added and the solution was extracted with EtOAc (3 × 15 mL). Combined organic fractions were washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, and concentrated to afford **10** as a red amorphous solid (177 mg, 99%): ¹H NMR (CDCl₃, 500 MHz) δ 8.17 (s, 1H), 6.09 (d, *J* = 1.6 Hz, 1H), 6.04 (s, 1H), 3.67 (d, *J* = 9.9 Hz, 3H), 2.08 (d, *J* = 4.1 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 160.3, 157.8, 155.4, 108.4, 93.9, 93.8, 55.0, 7.0; IR (film) ν_{max} 3445, 2924, 2853, 2359, 2332, 1653, 1636, 1456, 1080, 1022, 798, 669 cm⁻¹; HRMS (ESI⁺) *m/z*: [2M + H]⁺ calcd for C₈H₁₀O₃, 309.1338 found, 309.1332.

1,3-Bis(methoxymethoxy)benzene (12)⁶⁴

Sodium hydride (872 mg, 36.3 mmol) was added to resorcinol (1.00 g, 9.08 mmol) in anhydrous *N,N*-dimethylformamide (25.4 mL) at 0° C. After 30 min, methoxy methylchloride (2.76 mL,

36.3 mmol) was added and the resulting solution was warmed to rt over 12 h. The reaction was cooled to 0° C, quenched by the addition of saturated aqueous NaHCO₃, and extracted with EtOAc (3 × 30 mL). Combined organic fractions were washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 4:1 Hexane:EtOAc) to afford **12** as a yellow oil (1.75 g, 97%): ¹H NMR (CDCl₃, 400 MHz) δ 7.25-7.20 (m, 1H), 6.80 (d, *J* = 2.3 Hz, 1H), 6.75 (dd, *J* = 8.2, 2.4 Hz, 2H), 5.20 (s, 4H), 3.51 (s, 6H).

2-Benzyl-1,3-bis(methoxymethoxy)benzene (13)

A solution of **12** (500 mg, 2.52 mmol) in anhydrous THF (2.02 mL) was added dropwise to a solution of ^{*n*}BuLi (2.5 M in hexanes, 1.51 mL, 3.78 mmol) in anhydrous THF (1.65 mL) at rt. After 1 h, the solution was cooled to -40° C and benzyl bromide (1.22 mL, 10.10 mmol) was added. The resulting solution was warmed to rt over 12 h, and the reaction was quenched by the addition of saturated aqueous NH₄Cl. Water (5 mL) was added and the solution was extracted with CH₂Cl₂ (3 × 10 mL). Combined organic fractions were dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 4:1; Hexane:EtOAc) to afford **13** as a yellow oil (214 mg, 30%): ¹H NMR (CDCl₃, 500 MHz) δ 7.17 (d, *J* = 7.9 Hz, 2H), 7.17-7.12 (m, 2H), 7.06-7.02 (m, 2H), 6.71 (d, *J* = 8.3 Hz, 2H), 5.09 (s, 4H), 4.00 (s, 2H), 3.29 (s, 6H); ¹³C NMR (CDCl₃, 125 MHz) δ 155.9 (2C), 141.6, 128.5 (2C), 128.0 (2C), 127.5, 125.4, 119.4, 107.7 (2C), 94.3 (2C), 56.0 (2C), 29.1; IR (film) ν_{\max} 2953, 2930, 1595, 1470, 1452, 1254, 1153, 1097, 1043, 941, 922, 727, 698 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + Na]⁺ calcd for C₁₇H₂₀O₄, 311.1259; found, 311.1201.

2-Benzylbenzene-1,3-diol (14)⁶⁵

A solution of **13** (214 mg, 0.74 mmol) in MeOH (6.20 mL) was treated dropwise with 3M HCl (0.22 mL, 5.92 mmol), then heated to reflux for 1 h. Water (10 mL) was added and the solution was extracted with EtOAc (3 × 15 mL). Combined organic fractions were washed with saturated aqueous NaCl, dried (Na₂SO₄), and concentrated to afford **14** as a red amorphous solid (149 mg, 99%). ¹H NMR (CDCl₃, 400 MHz) δ 7.31 (d, *J* = 6.6 Hz, 4H), 7.25-7.19 (m, 1H), 7.01 (t, *J* = 8.1 Hz, 1H), 6.44 (d, *J* = 8.1 Hz, 2H), 4.82 (s, 2H), 4.09 (s, 2H).

2-Iodo-1,3-bis(methoxymethoxy)benzene (15)

n-Butyllithium (2.5M in hexanes, 0.22 mL, 0.56 mmol) was added to a solution of **12** (100 mg, 0.50 mmol) in anhydrous THF (790 μL) at 0° C. After 5 min, iodine (141 mg, 0.56 mmol) in anhydrous THF (320 μL) was added. After 2 h at rt, the reaction was quenched via dropwise addition of MeOH and the solvent was concentrated. Water (5 mL) was added and the solution was extracted with EtOAc (3 × 10 mL). Combined organics were washed with saturated aqueous Na₂S₂O₃, saturated aqueous NaCl, dried (Na₂SO₄), filtered, and concentrated to afford **15** as a brown oil (129 mg, 79%): ¹H NMR (CDCl₃, 100 MHz) δ 7.25-7.18 (m, 1H), 6.79-6.71 (m, 2H), 5.27 (s, 2H), 5.18 (s, 2H), 3.54 (s, 3H), 3.50 (s, 3H); IR (film) ν_{\max} 2953, 2924, 2853, 1458, 1377 cm⁻¹.

2,6-Bis(methoxymethoxy)biphenyl (16)

Anhydrous toluene (2.0 mL) was added to a flask charged with Pd₂(dba)₃ (56.3 mg, 0.062 mmol), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (50.5 mg, 0.12 mmol), phenylboronic acid (281 mg, 2.31 mmol), and potassium phosphate (979 mg, 4.61 mmol) at rt. After 15 min, a solution of **15** (500 mg, 1.54 mmol) in anhydrous toluene (1.0 mL) was added and the resulting solution was heated to reflux for 12 h. Upon cooling to rt, ether was added, the solution was filtered through SiO₂ and concentrated to give **16** as a colorless amorphous solid (418 mg, 99%): ¹H NMR (CDCl₃, 500 MHz) δ 7.35-7.28 (m, 2H), 7.28-7.25 (m, 2H), 7.18-7.15 (m, 2H), 6.83 (d, *J* = 8.3 Hz, 2H), 4.96 (s, 4H), 3.24 (s, 6H); ¹³C NMR

(CDCl₃, 125 MHz) δ 155.3, 155.0, 134.3, 130.8, 129.5, 128.7, 128.0, 127.6, 126.8, 122.6, 109.4 (2C), 94.9 (2C), 56.0 (2C); IR (film) ν_{\max} 2955, 2928, 2901, 2359, 2341, 1587, 1466, 1439, 1400, 1244, 1153, 1099, 1080, 1041, 922, 764, 733, 700 cm⁻¹; HRMS (ESI⁺) m/z : [M + Na]⁺ calcd for C₁₆H₁₈O₄, 297.1103; found, 297.1052.

Biphenyl-2,6-diol (17)⁶⁶

A solution of **16** (400 mg, 1.46 mmol) in MeOH (12.0 mL) at rt was treated dropwise with 3M HCl (430 μ L, 11.7 mmol), then heated to reflux for 1 h. Water (15 mL) was added and the solution was extracted with EtOAc (3 \times 20 mL). Combined organic fractions were washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, and concentrated to afford **17** as an orange amorphous solid (269 mg, 99%): ¹H NMR (CDCl₃, 400 MHz) δ 7.60 (d, J = 7.6 Hz, 2H), 7.53-7.49 (m, 1H), 7.46-7.44 (m, 2H), 7.18 (t, J = 8.2 Hz, 1H), 6.62 (d, J = 8.2 Hz, 2H), 4.84 (s, 1H), 4.83 (s, 1H).

2-Methoxybenzene-1,3-diol (19)⁶⁷

Lithium carbonate (281 mg, 1.98 mmol) was added to pyrogallol (100 mg, 0.79 mmol) in *N,N*-dimethylformamide (3.0 mL) at rt. After 5 min, methyl iodide (130 μ L, 1.98 mmol) was added and the resulting solution was heated to 50° C for 48 h. Upon cooling to rt, water (20 mL) was added and the solution was extracted with EtOAc (3 \times 20 mL). Combined organic fractions were dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 5:1 \rightarrow 1:1 Hexane:EtOAc) to afford **19** as a colorless amorphous solid (44.2 mg, 34%): ¹H NMR (CDCl₃, 400 MHz) δ 6.89 (td, J = 8.0, 0.9 Hz, H), 6.53 (dd, J = 8.2, 0.8 Hz, 2H), 5.83 (bs, 2H), 3.90 (s, 3H).

Benzyl 7-hydroxy-6-methoxy-8-methyl-2-oxo-2H-chromen-3-ylcarbamate (23a)

A solution of **6a** (183 mg, 1.19 mmol) and enamine **22** (331 mg, 1.19 mmol) in glacial acetic acid (7.40 mL) was heated to reflux for 40 h. Upon cooling to rt, the solution was extracted with EtOAc (3 \times 20 mL); combined organic fractions were dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 100:1 CH₂Cl₂:Acetone) to afford **23a** as a yellow amorphous solid (195 mg, 46%): ¹H NMR (CDCl₃, 400 MHz) δ 8.27 (s, 1H), 7.54 (s, 1H), 7.43-7.37 (m, 4H), 6.77 (s, 1H), 6.07 (s, 1H), 5.25 (s, 2H), 3.96 (s, 3H), 2.37 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 159.0, 153.3 (2C), 145.7, 144.1, 144.0, 135.7, 128.7, 128.5, 128.2 (2C), 122.5, 121.6, 112.1, 111.6, 104.5, 67.4, 56.3, 8.2; IR (film) ν_{\max} 2910, 2359, 2339, 1693, 1537, 1354, 1209, 1078, 1024 cm⁻¹; HRMS (ESI⁺) m/z : [M + Na]⁺ calcd for C₁₉H₁₇NO₆, 378.0954; found, 378.0936.

Benzyl 7-hydroxy-8-methyl-2-oxo-6-propoxy-2H-chromen-3-ylcarbamate (23b)

A solution of **6b** (390 mg, 2.14 mmol) and enamine **22** (596 mg, 2.14 mmol) in glacial acetic acid (13.4 mL) was heated to reflux for 36 h. Upon cooling to rt, the precipitated yellow solid was collected by filtration, washed with water, recrystallized from MeOH/water, and extracted with EtOAc (3 \times 20 mL). Combined organic fractions were washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 100:1 CH₂Cl₂:Acetone) and recrystallized from MeOH/water to afford **23b** as a yellow amorphous solid (278 mg, 34%): ¹H NMR (CD₂Cl₂, 400 MHz) δ 8.26 (s, 1H), 7.56 (s, 1H), 7.47-7.38 (m, 5H), 6.84 (s, 1H), 6.28 (s, 1H), 5.25 (s, 2H), 4.09 (t, J = 6.6 Hz, 2H), 2.36 (s, 3H), 1.93-1.88 (m, 2H), 1.10 (t, J = 7.4 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 158.0, 152.2, 144.9, 142.9, 142.3, 134.6, 129.0, 127.6, 127.5 (2C), 127.2 (2C), 121.5, 120.5, 110.9, 110.5, 104.4, 69.8, 66.3, 21.4, 9.4, 7.1; IR (film) ν_{\max} 2957, 2920, 2851, 2359, 2341, 1693, 1537, 1358, 1277, 1080, 1024, 910 cm⁻¹; HRMS (ESI⁺) m/z : [M + H]⁺ calcd for C₂₁H₂₁NO₆, 384.1447; found, 384.1447.

Benzyl 7-hydroxy-6-isopropoxy-8-methyl-2-oxo-2H-chromen-3-ylcarbamate (23c)

A solution of **6c** (142 mg, 0.78 mmol) and enamine **22** (217 mg, 0.78 mmol) in glacial acetic acid (4.90 mL) was heated to reflux for 40 h. Upon cooling to rt, the solution was extracted with EtOAc (3 × 10 mL); combined organic fractions were dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford **23c** as a yellow amorphous solid (159 mg, 53%): ¹H NMR (CD₂Cl₂, 400 MHz) δ 8.26 (s, 1H), 7.56 (s, 1H), 7.44-7.38 (m, 5H), 6.85 (s, 1H), 6.31 (s, 1H), 5.25 (s, 2H), 4.66 (quintet, *J* = 6.1 Hz, 1H), 2.35 (s, 3H), 1.42 (d, *J* = 6.0 Hz, 6H); ¹³C NMR (CDCl₃, 125 MHz) δ 159.1, 154.9, 146.7, 143.9 (2C), 142.0, 135.7, 128.7 (2C), 128.5, 128.2 (2C), 122.6 (2C), 111.6, 107.0, 72.3, 67.4, 22.1 (2C), 8.2; IR (film) ν_{\max} 3400, 2924, 2853, 2359, 1817, 1699, 1524, 1412, 1354, 1300, 1221, 1204, 1113, 1076, 1022, 824 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₂₁H₂₁NO₆, 384.1447; found, 384.1452.

Benzyl 7-hydroxy-5-methoxy-8-methyl-2-oxo-2H-chromen-3-ylcarbamate (23d)

A solution of **10** (251 mg, 1.63 mmol) and enamine **22** (680 mg, 2.44 mmol) in glacial acetic acid (10.2 mL) was heated to reflux for 40 h. Upon cooling to rt, the solution was extracted with EtOAc (3 × 15 mL); combined organic fractions were dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 40:1 → 20:1; CH₂Cl₂:Acetone) to afford **23d** as a yellow amorphous solid (204 mg, 35%): ¹H NMR (CD₂Cl₂, 400 MHz) δ 8.48 (s, 1H), 7.46-7.38 (m, 6H), 6.38 (s, 1H), 5.25 (s, 2H), 5.15 (s, 1H), 3.87 (s, 3H), 2.23 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 159.1, 155.8, 154.3, 153.2, 149.8, 137.0, 128.7, 128.6, 128.6, 128.2, 128.2, 109.3, 109.0, 108.5, 105.6, 96.9, 70.8, 60.2, 7.3; IR (film) ν_{\max} 3406, 2935, 2837, 1713, 1670, 1607, 1529, 1501, 1364, 1242, 1101, 1051, 991, 966, 735 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + Na]⁺ calcd for C₁₉H₁₇NO₆, 378.0954; found, 378.0974.

Benzyl 8-benzyl-7-hydroxy-2-oxo-2H-chromen-3-ylcarbamate (23e)

A solution of **14** (115 mg, 0.57 mmol) and enamine **22** (160 mg, 0.57 mmol) in glacial acetic acid (4.00 mL) was heated to reflux for 40 h. Upon cooling to rt, the solution was extracted with EtOAc (3 × 10 mL); combined organic fractions were dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 100:1; CH₂Cl₂:Acetone), followed by recrystallization from MeOH to afford **23e** as an orange amorphous solid (296 mg, 48%): ¹H NMR (CD₂Cl₂, 400 MHz) δ 8.29 (s, 1H), 7.53 (s, 1H), 7.46-7.38 (m, 4H), 7.37-7.27 (m, 4H), 7.23-7.19 (m, 2H), 7.01 (t, *J* = 8.1 Hz, 1H), 6.86 (d, *J* = 8.4 Hz, 1H), 6.46 (d, *J* = 8.1 Hz, 1H), 5.25 (s, 2H), 4.25 (s, 2H), 4.06 (s, 1H); ¹³C NMR (CDCl₃, 125 MHz) δ 157.7, 154.3, 153.9, 152.2, 148.0, 137.9, 134.5, 127.6, 127.6, 127.6, 127.6, 127.5, 127.3, 127.2, 127.4, 126.6, 125.4, 125.3, 121.4, 120.4, 114.0, 112.6, 66.5, 27.5; IR (film) ν_{\max} 3381, 2957, 2928, 2359, 2341, 1693, 1607, 1526, 1466, 1454, 1383, 1366, 1219, 1204, 1076, 1045, 764, 737, 700 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₂₄H₁₉NO₅, 402.1341; found, 402.1341.

Benzyl 7-hydroxy-2-oxo-8-phenyl-2H-chromen-3-ylcarbamate (23f)

A solution of **17** (400 mg, 2.15 mmol) and enamine **22** (598 mg, 2.15 mmol) in glacial acetic acid (14.3 mL) was heated to reflux for 40 h. Upon cooling to rt, the solution was extracted with EtOAc (3 × 30 mL); combined organic fractions were dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 100:1; CH₂Cl₂:Acetone), then recrystallized from MeOH to afford **23f** as an orange amorphous solid (264 mg, 27%): ¹H NMR (CDCl₃, 500 MHz) δ 8.25 (s, 1H), 7.51-7.48 (m, 2H), 7.43-7.40 (m, 2H), 7.35-7.29 (m, 8H), 6.94 (d, *J* = 8.6 Hz, 1H), 5.16 (s, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 158.5 (2C), 154.3, 153.2, 147.7, 135.6, 130.9, 130.6, 130.5, 129.8, 129.4, 129.2 (2C), 128.7 (2C), 128.6, 128.3, 127.8, 122.2, 121.6, 113.3, 113.5, 67.5; IR (film) ν_{\max} 3398, 2957, 2926,

2854, 1815, 1699, 1601, 1524, 1383, 1366, 1308, 1215, 1045, 1009, 764, 750, 698 cm^{-1} ; HRMS (ESI⁺) m/z : [M + H]⁺ calcd for C₂₃H₁₇NO₅, 388.1185; found, 388.1214.

Benzyl 7-hydroxy-8-methoxy-2-oxo-2*H*-chromen-3-ylcarbamate (23g)

A solution of **19** (1.10 g, 7.86 mmol) and enamine **22** (2.18 g, 7.86 mmol) in glacial acetic acid (60.0 mL) was heated to reflux for 90 h. Upon cooling to rt, the solution was extracted with EtOAc (3 × 50 mL); combined organic fractions were washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 11:1; Hexane:EtOAc → EtOAc) then recrystallized from MeOH/water to afford **23g** as a colorless amorphous solid (207 mg, 7.7%): ¹H NMR (CDCl₃, 400 MHz) δ 8.30 (s, 1H), 7.50 (s, 1H), 7.43-7.36 (m, 5H), 7.13 (d, J = 8.6 Hz, 1H), 6.97 (d, J = 7.9 Hz, 1H), 6.04 (s, 1H), 5.21 (s, 2H), 4.13 (s, 3H); ¹³C NMR (Acetone-*d*₆, 100 MHz) δ 157.3, 153.3, 151.5 (2C), 144.1, 136.5, 134.4, 128.4 (2C), 128.1, 128.0 (2C), 122.7, 121.6, 113.6, 113.2, 66.7, 60.7; IR (film) ν_{max} 2920, 2851, 2405, 2357, 1707, 1605, 1522, 1458, 1385, 1364, 1275, 1259, 1213, 1088, 1047, 750 cm^{-1} ; HRMS (ESI⁺) m/z : [M + Na]⁺ calcd for C₁₈H₁₅NO₆, 364.0797; found, 364.0776.

Benzyl 8-ethyl-7-hydroxy-2-oxo-2*H*-chromen-3-ylcarbamate (23h)

A solution of **21** (1.40 g, 10.1 mmol) and enamine **22** (2.80 g, 10.1 mmol) in glacial acetic acid (50.0 mL) was heated to reflux for 12 h. Upon cooling to rt, the solvent was concentrated. The residue was purified via column chromatography (SiO₂, 4:1 → 2:1; Hexane:EtOAc), then recrystallized from acetone/hexanes to afford **23h** as a colorless amorphous solid (600 mg, 17%). ¹H NMR (DMSO-*d*₆, 400 MHz) δ 9.07 (s, 1H), 8.12 (s, 1H), 7.46-7.32 (m, 6H), 6.86 (d, J = 8.4 Hz, 1H), 5.18 (s, 2H), 2.72 (q, J = 7.6 Hz, 2H), 1.11 (t, J = 7.6 Hz, 3H); ¹³C NMR (DMSO-*d*₆, 125 MHz) δ 158.0, 157.1, 153.8 (2C), 149.5, 136.4, 128.4 (2C), 127.9, 127.8, 127.2, 125.8, 120.4, 116.6, 112.8, 111.4, 66.1, 15.7, 13.5; IR (film) ν_{max} 3391, 3339, 2964, 2870, 2357, 1732, 1682, 1620, 1524, 1506, 1454, 1364, 1277, 1188, 1097, 1024, 752, 698 cm^{-1} ; HRMS (ESI⁺) m/z : [M + H]⁺ calcd for C₁₉H₁₇NO₅, 340.1185; found, 340.1181.

Benzyl 6-methoxy-7-((3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyran-4-yloxy)-8-methyl-2-oxo-2*H*-chromen-3-ylcarbamate (25a)

Boron trifluoride etherate (5.30 μL , 0.042 mmol) was added to **23a** (50.0 mg, 0.14 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (171 mg, 0.47 mmol) in anhydrous CH₂Cl₂ (3.00 mL). After stirring at rt for 14 h, triethylamine (150 μL) was added and the solvent was concentrated. The residue was purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to give **25a** as a colorless foam (74.0 mg, 95%): ¹H NMR (CD₂Cl₂, 400 MHz) δ 8.29 (s, 1H), 7.64 (s, 1H), 7.47-7.39 (m, 5H), 6.91 (s, 1H), 5.52 (d, J = 3.4 Hz, 1H), 5.26 (s, 2H), 5.23 (dd, J = 8.4, 3.5 Hz, 1H), 4.95 (t, J = 8.2 Hz, 1H), 3.92 (s, 3H), 3.60 (s, 3H), 3.33 (d, J = 8.0 Hz, 1H), 2.42 (s, 3H), 1.38 (s, 3H), 1.33 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 157.6, 152.7, 152.1, 148.1, 144.8, 141.8, 134.5, 127.8, 127.7, 127.5, 127.3, 122.3, 120.2, 119.8, 115.1, 109.6, 105.2, 98.3, 82.0, 77.1, 66.5, 65.5, 59.4, 57.4, 55.1, 26.0, 20.9, 8.9; IR (film) ν_{max} 2957, 2928, 2854, 2359, 2341, 1817, 1709, 1522, 1464, 1389, 1371, 1205, 1174, 1111, 1072, 1034, 957, 800 cm^{-1} ; HRMS (ESI⁺) m/z : [M + H]⁺ calcd for C₂₈H₂₉NO₁₁, 556.1819; found, 556.1822.

Benzyl 7-((3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyran-4-yloxy)-8-methyl-2-oxo-6-propoxy-2*H*-chromen-3-ylcarbamate (25b)

Boron trifluoride etherate (16.7 μL , 0.13 mmol) was added to **23b** (170 mg, 0.44 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (643 mg, 1.77 mmol) in anhydrous CH₂Cl₂ (11.1 mL). After stirring at rt for 48 h, triethylamine (150 μL) was added and the solvent was concentrated.

The residue was purified via column chromatography (SiO₂, 100:1 → 40:1 CH₂Cl₂:Acetone) to give **25b** as a colorless foam (246 mg, 95%): ¹H NMR (CDCl₃, 500 MHz) δ 8.17 (s, 1H), 7.35-7.27 (m, 5H), 6.84 (s, 1H), 5.96 (s, 1H), 5.15 (s, 2H), 4.99 (d, *J* = 7.5 Hz, 1H), 4.59 (d, *J* = 9.7 Hz, 1H), 4.23 (d, *J* = 9.6 Hz, 1H), 3.97 (t, *J* = 6.6 Hz, 1H), 3.82-3.75 (m, 2H), 3.37 (s, 3H), 1.84-1.79 (m, 2H), 1.51 (s, 3H), 1.41 (s, 3H), 1.18 (s, 3H), 1.00 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 157.8, 154.3, 152.2, 151.8, 146.7, 144.2, 142.9, 134.6, 127.8, 127.6, 127.5, 127.5, 127.2, 121.0, 120.9, 111.1, 105.3, 101.7, 91.6, 85.7, 82.8, 80.0, 69.8, 58.1, 54.8, 28.3, 28.2, 22.4, 21.3, 9.4; IR (film) ν_{\max} 2961, 2939, 2906, 2359, 2341, 1811, 1757, 1726, 1522, 1445, 1371, 1267, 1175, 1113, 1086, 825, 768 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + Na]⁺ calcd for C₃₀H₃₃NO₁₁, 606.1952; found, 606.1950.

Benzyl 6-isopropoxy-7-((3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyran-4-yloxy)-8-methyl-2-oxo-2*H*-chromen-3-ylcarbamate (25c)

Boron trifluoride etherate (1.30 μL, 0.010 mmol) was added to **23c** (13.0 mg, 0.034 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1.3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (83.0 mg, 0.23 mmol) in anhydrous CH₂Cl₂ (1.30 mL). After stirring at rt for 1.5 h, triethylamine (150 μL) was added and the solvent was concentrated. The residue was purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to give **25c** as a colorless foam (19.0 mg, 95%): ¹H NMR (CDCl₃, 500 MHz) δ 8.17 (s, 1H), 7.51 (s, 1H), 7.35 (s, 1H), 7.34-7.33 (m, 4H), 6.74 (s, 1H), 5.54 (dd, *J* = 9.2, 1.2 Hz, 1H), 5.16 (s, 2H), 4.87-4.84 (m, 1H), 4.73 (dd, *J* = 7.9, 1.9 Hz, 1H), 4.51 (quintet, *J* = 6.0 Hz, 1H), 3.52 (s, 3H), 3.28 (d, *J* = 4.8 Hz, 1H), 2.33 (s, 3H), 1.80-1.77 (m, 6H), 1.30 (s, 3H), 1.27 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 161.6, 158.6, 153.2, 153.1, 147.1, 146.8, 142.5, 135.5, 128.7, 128.6, 128.3, 123.3, 121.4, 121.1, 116.2, 108.6, 99.4, 83.1, 79.9, 76.1, 74.7, 72.2, 68.0, 60.5, 27.1, 25.6, 21.9, 21.6, 21.0, 10.1; IR (film) ν_{\max} 2955, 2922, 2853, 2359, 2339, 1819, 1711, 1520, 1464, 1375, 1171, 1111, 1034, 962, 822, 766 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₃₀H₃₃NO₁₁, 584.2132; found, 584.2111.

Benzyl 5-methoxy-7-((3*aR*,4*R*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyran-4-yloxy)-8-methyl-2-oxo-2*H*-chromen-3-ylcarbamate (25d)

Boron trifluoride etherate (18.5 μL, 0.15 mmol) was added to **23d** (174 mg, 0.49 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1.3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (621 mg, 1.71 mmol) in anhydrous CH₂Cl₂ (11.0 mL). After stirring at rt for 14 h, triethylamine (150 μL) was added and the solvent was concentrated. The residue was purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to give **25d** as a colorless foam (200 mg, 74%): ¹H NMR (CDCl₃, 500 MHz) δ 8.49 (s, 1H), 7.34-7.27 (m, 5H), 6.67 (s, 1H), 6.60 (s, 1H), 5.69 (s, 2H), 5.16 (d, *J* = 5.3 Hz, 1H), 4.89 (t, *J* = 7.8 Hz, 1H), 4.63 (dd, *J* = 7.9, 2.4 Hz, 1H), 3.83 (s, 3H), 3.37 (s, 3H), 3.15 (d, *J* = 8.0 Hz, 1H), 2.16 (s, 3H), 2.16 (s, 3H), 2.12 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 158.9, 156.0, 155.2, 154.2, 153.1 (2C), 149.4, 135.7, 128.7 (2C), 128.5, 128.2 (2C), 120.8, 117.4, 106.6, 105.4, 94.6, 94.1, 82.9, 67.4, 60.6, 60.6, 56.1, 56.0, 22.2, 22.0, 7.9; IR (film) ν_{\max} 2955, 2924, 2853, 1817, 1713, 1526, 1209, 1105, 1072, 1034, 976, 808 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₂₈H₂₉NO₁₁, 556.1819; found, 556.1826.

Benzyl 8-benzyl-7-((3*aR*,4*R*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyran-4-yloxy)-2-oxo-2*H*-chromen-3-ylcarbamate (25e)

Boron trifluoride etherate (7.80 μL, 0.062 mmol) was added to **23e** (80.0 mg, 0.21 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1.3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (299 mg, 0.83 mmol) in anhydrous CH₂Cl₂ (5.20 mL). After stirring at rt for 48 h, triethylamine (150 μL) was added and the solvent was concentrated. The residue was purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to give

25e as a colorless foam (47.0 mg, 39%): ^1H NMR (CDCl_3 , 500 MHz) δ 8.22 (s, 1H), 7.46 (s, 1H), 7.35-7.27 (m, 5H), 7.17-7.06 (m, 5H), 6.86 (d, $J = 10$ Hz, 1H), 6.01 (d, $J = 10$ Hz, 1H), 5.65 (d, $J = 1.6$ Hz, 1H), 5.23 (s, 2H), 5.16 (s, 2H), 4.77-4.70 (m, 1H), 4.10 (s, 1H), 3.50 (s, 3H), 3.28 (s, 1H), 3.16 (d, $J = 7.4$ Hz, 1H), 1.25 (s, 3H), 1.18 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 155.1, 153.2 (2C), 153.1, 148.6 (2C), 139.6 (2C), 128.7, 128.6 (2C), 128.4 (2C), 128.3 (2C), 128.3 (2C), 126.5, 126.2, 123.1, 122.4, 121.7, 117.6, 114.9, 111.5, 94.7, 82.8, 67.6, 60.6 (2C), 29.7, 27.6, 21.9; IR (film) ν_{max} 2926, 2854, 2359, 2341, 1811, 1709, 1607, 1522, 1456, 1381, 1366, 1259, 1209, 1171, 1078, 1049, 968, 766, 700 cm^{-1} ; HRMS (ESI⁺) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{33}\text{H}_{31}\text{NO}_{10}$, 602.2026; found, 602.2053.

Benzyl 7-((3*aR*,4*R*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyran-4-yloxy)-2-oxo-8-phenyl-2*H*-chromen-3-ylcarbamate (25f)

Boron trifluoride etherate (14.6 μL , 0.12 mmol) was added to **23f** (155 mg, 0.39 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1.3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (560 mg, 1.55 mmol) in anhydrous CH_2Cl_2 (9.70 mL). After stirring at rt for 48 h, triethylamine (150 μL) was added and the solvent was concentrated. The residue was purified via column chromatography (SiO_2 , 100:1 \rightarrow 40:1 CH_2Cl_2 :Acetone) to give **25f** as a colorless foam (225 mg, 99%): ^1H NMR (CD_2Cl_2 , 400 MHz) δ 8.37 (s, 1H), 7.75-7.73 (m, 2H), 7.60-7.36 (m, 10H), 7.32 (d, $J = 8.8$ Hz, 1H), 5.77 (d, $J = 1.7$ Hz, 1H), 5.26 (s, 2H), 4.76-4.68 (m, 1H), 4.36-4.28 (m, 1H), 3.56 (s, 3H), 3.28 (d, $J = 7.2$ Hz, 1H), 1.37 (s, 3H), 1.31 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 157.2, 153.0 (2C), 152.1 (2C), 152.1, 134.4, 129.9, 129.8, 129.4, 127.7 (2C), 127.5, 127.2 (2C), 127.1 (2C), 127.0, 126.3, 121.5 (2C), 120.3, 111.2 (2C), 93.9, 81.9, 66.5, 59.4 (3C), 20.9 (2C); IR (film) ν_{max} 3400, 2959, 2926, 2853, 2359, 2341, 1819, 1715, 1601, 1522, 1381, 1366, 1261, 1215, 1173, 1111, 1059, 970, 800, 700 cm^{-1} ; HRMS (ESI⁺) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{32}\text{H}_{29}\text{NO}_{10}$, 588.1870; found, 588.1846.

Benzyl 8-methoxy-7-((3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyran-4-yloxy)-2-oxo-2*H*-chromen-3-ylcarbamate (25g)

Boron trifluoride etherate (17.3 μL , 0.14 mmol) was added to **23g** (157 mg, 0.46 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1.3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (665 mg, 1.83 mmol) in anhydrous CH_2Cl_2 (11.5 mL). After stirring at rt for 24 h, triethylamine (150 μL) was added and the solvent was concentrated. The residue was purified via column chromatography (SiO_2 , 40:1 \rightarrow 10:1 CH_2Cl_2 :Acetone) to give **25g** as a colorless foam (237 mg, 95%): ^1H NMR (CDCl_3 , 500 MHz) δ 8.20 (s, 1H), 7.48 (s, 1H), 7.33-7.29 (m, 5H), 7.09 (dd, $J = 14.2$, 8.8 Hz, 2H), 5.72 (d, $J = 1.8$ Hz, 1H), 5.16 (s, 2H), 5.02 (dd, $J = 7.8$, 1.8 Hz, 1H), 4.89 (t, $J = 7.8$ Hz, 1H), 3.88 (s, 3H), 3.52 (s, 3H), 3.21 (d, $J = 7.8$ Hz, 1H), 1.27 (s, 3H), 1.17 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 158.0, 153.3, 153.2, 153.1, 149.8, 143.8, 137.1, 135.5, 128.7 (2C), 128.6, 128.3 (2C), 122.7, 122.2, 121.4, 116.1, 113.7, 95.3, 74.7, 72.9, 67.6, 61.9, 60.7, 60.6, 29.7, 29.4; IR (film) ν_{max} 3400, 3319, 2984, 2935, 2359, 1815, 1715, 1609, 1526, 1464, 1383, 1364, 1285, 1213, 1175, 1111, 1063, 968, 764, 737, 700 cm^{-1} ; HRMS (ESI⁺) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{27}\text{H}_{27}\text{NO}_{11}$, 564.1482; found, 564.1455.

Benzyl 8-ethyl-7-((3*aR*,4*R*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyran-4-yloxy)-2-oxo-2*H*-chromen-3-ylcarbamate (25h)

Boron trifluoride etherate (19.0 μL , 0.15 mmol) was added to **23h** (171 mg, 0.51 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1.3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (183 mg, 0.51 mmol) in anhydrous CH_2Cl_2 (11.0 mL). After stirring at rt for 24 h, triethylamine (150 μL) was added and the solvent was concentrated. The residue was purified via column chromatography (SiO_2 , 40:1 CH_2Cl_2 :Acetone) to give **25h** as a colorless foam (138 mg, 51%): ^1H NMR (CD_2Cl_2 , 400 MHz) δ 8.29 (s, 1H), 7.62 (s,

1H), 7.47-7.38 (m, 5H), 7.36 (d, $J = 8.8$ Hz, 1H), 7.19 (d, $J = 8.4$ Hz, 1H), 5.81 (d, $J = 2.4$ Hz, 1H), 5.25 (s, 2H), 5.10 (dd, $J = 8.0, 2.0$ Hz, 1H), 5.02 (t, $J = 7.8$ Hz, 1H), 3.55 (s, 3H), 3.41 (d, $J = 7.2$ Hz, 1H), 2.87 (q, $J = 7.4$ Hz, 2H), 1.42 (s, 3H), 1.28 (s, 3H), 1.21 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (CD_2Cl_2 , 100 MHz) δ 158.5, 154.8, 153.2, 153.1, 148.4, 136.0, 128.6 (2C), 128.4, 128.1, 125.6, 122.4, 121.5, 120.7, 114.8, 111.4, 94.8, 82.7, 77.9, 77.2, 76.6, 67.3, 60.3, 27.3, 22.3, 16.4, 13.6; IR (film) ν_{max} 3400, 2980, 2937, 2359, 2339, 1817, 1711, 1607, 1524, 1383, 1366, 1227, 1205, 1175, 1101, 1040, 906, 768, 737, 700 cm^{-1} ; $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{28}\text{H}_{29}\text{NO}_{10}$, 562.1689; found, 562.1689.

***N*-(7-((2*S*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-6-methoxy-8-methyl-2-oxo-2*H*-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide (26a)**

Palladium on carbon (10%, 20.0 mg) was added to **25a** (100 mg, 0.18 mmol) in anhydrous THF (5.00 mL) and the solution was placed under an atmosphere of H_2 . After 6.5 h, the solution was filtered through SiO_2 (1:1 CH_2Cl_2 :Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (56.0 mg, 75%).

EDCI (21.4 mg, 0.11 mmol) and 3',6-dimethoxybiphenyl-3-carboxylic acid (23.1 mg, 0.089 mmol) were added to the amine (18.7 mg, 0.045 mmol) in 30% pyridine/ CH_2Cl_2 (0.70 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO_2 , 40:1 CH_2Cl_2 :Acetone) to afford a colorless solid, which was used without further purification (10.5 mg, 36%).

Triethylamine (150 μL) was added to the carbonate (10.4 mg, 0.016 mmol) in MeOH (2.50 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO_2 , 20:1; CH_2Cl_2 :MeOH) to afford **26a** as a colorless amorphous solid (2.00 mg, 20%, 5% over 3 steps): ^1H NMR (CDCl_3 , 500 MHz) δ 8.73 (s, 1H), 8.70 (d, $J = 5.4$ Hz, 1H), 7.84 (td, $J = 6.2, 2.4$ Hz, 1H), 7.82 (s, 1H), 7.30 (t, $J = 8.0$ Hz, 1H), 7.06 (d, $J = 7.8$ Hz, 1H), 7.03-7.00 (m, 2H), 6.88-6.86 (m, 1H), 6.81 (s, 1H), 4.99 (d, $J = 6.6$ Hz, 1H), 4.24 (t, $J = 4.2$ Hz, 1H), 4.00 (dd, $J = 6.5, 3.7$ Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.83 (s, 3H), 3.80 (d, $J = 7.4$ Hz, 1H), 3.45 (s, 3H), 3.08 (d, $J = 4.7$ Hz, 1H), 2.67 (s, 1H), 2.42 (s, 3H), 1.28 (d, $J = 8.1$ Hz, 3H), 1.18 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 164.6, 158.9, 158.3, 158.2, 148.2, 145.6, 142.5, 137.5, 130.1, 129.0, 128.2, 127.2, 124.9, 122.5, 122.2, 121.2, 121.0, 115.1, 144.2, 112.1, 110.0, 105.4, 101.3, 81.7, 76.8, 69.0, 68.0, 59.1, 55.3, 54.9, 54.3, 28.3, 28.2, 9.1; IR (film) ν_{max} 2961, 2928, 1713, 1670, 1601, 1464, 1383, 1261, 1094, 1022, 798, 700 cm^{-1} ; HRMS (ESI $^+$) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{34}\text{H}_{37}\text{NO}_{11}$, 636.2445; found, 636.2477.

***N*-(7-((2*S*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-8-methyl-2-oxo-6-propoxy-2*H*-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide (26b)**

Palladium on carbon (10%, 85.0 mg) was added to **25b** (425 mg, 0.7283 mmol) in anhydrous THF (4.90 mL) and the solution was placed under an atmosphere of H_2 . After 6.5 h, the solution was filtered through SiO_2 (1:1 CH_2Cl_2 :Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (325 mg, 99%).

EDCI (116 mg, 0.60 mmol) and 3',6-dimethoxybiphenyl-3-carboxylic acid (125 mg, 0.4821 mmol) were added to the amine (108 mg, 0.2410 mmol) in 30% pyridine/ CH_2Cl_2 (6.70 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO_2 , 3:1 Hexane:Ether \rightarrow 20:1 CH_2Cl_2 :Acetone) to afford a colorless solid, which was used without further purification (51.0 mg, 31%).

Triethylamine (150 μL) was added to the carbonate (51.0 mg, 0.074 mmol) in MeOH (2.50 mL). After 48 h, the solvent was concentrated and the residue purified via column chromatography (SiO_2 , 40:1 CH_2Cl_2 :Acetone) to afford **26b** as a colorless amorphous solid

(22.8 mg, 47%, 14% over 3 steps): ^1H NMR (CD_2Cl_2 , 400 MHz) δ 8.79 (s, 1H), 8.78 (s, 1H), 7.96 (dd, $J = 8.6, 2.4$ Hz, 1H), 7.91 (d, $J = 2.4$ Hz, 1H), 7.39 (t, $J = 7.9$ Hz, 1H), 7.16-7.11 (m, 2H), 6.97-6.94 (m, 2H), 5.97 (s, 1H), 5.14 (d, $J = 6.5$ Hz, 1H), 4.31 (t, $J = 3.5$ Hz, 1H), 4.12-4.06 (m, 2H), 4.03 (dd, $J = 6.8, 1.8$ Hz, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 3.65 (s, 1H), 3.53 (s, 3H), 3.17 (d, $J = 4.8$ Hz, 1H), 2.80 (s, 1H), 2.48 (s, 3H), 1.95-1.90 (m, 2H), 1.37 (s, 3H), 1.35 (s, 3H), 1.11 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 165.0, 164.6, 158.8, 158.3, 147.7, 145.7, 142.3, 137.8, 137.5, 131.3, 129.0, 128.2, 127.2, 124.9, 122.3, 121.2, 121.0, 115.111, 114.2, 112.1, 110.0, 106.2, 101.1, 81.7, 70.0, 69.0, 68.0, 64.8, 59.1, 54.9, 54.3, 24.7, 24.0, 21.3, 9.5, 9.1; IR (film) ν_{max} 3398, 3196, 2964, 2935, 2359, 2330, 1705, 1580, 1526, 1504, 1381, 1242, 1124, 1094, 939, 808, 760, 735 cm^{-1} ; HRMS (ESI⁺) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{36}\text{H}_{41}\text{NO}_{11}$, 664.2758; found, 664.2754.

***N*-(7-((2*S*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-6-isopropoxy-8-methyl-2-oxo-2*H*-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide (26c)**

Palladium on carbon (10%, 11 mg) was added to **25c** (54.5 mg, 0.093 mmol) in anhydrous THF (600 μL) and the solution was placed under an atmosphere of H_2 . After 12 h, the solution was filtered through SiO_2 (1:1 CH_2Cl_2 :Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (42.0 mg, 99%).

EDCI (14.9 mg, 0.078 mmol) and 3',6-dimethoxybiphenyl-3-carboxylic acid (16 mg, 0.062 mmol) were added to the amine (14.0 mg, 0.031 mmol) in 30% pyridine/ CH_2Cl_2 (900 μL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO_2 , 3:1 Hexane:Ether \rightarrow 40:1 CH_2Cl_2 :Acetone) to afford a colorless solid, which was used without further purification (17.5 mg, 82%).

Triethylamine (150 μL) was added to the carbonate (17.5 mg, 0.025 mmol) in MeOH (2.50 mL) and CH_2Cl_2 (2.50 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO_2 , 10:1 CH_2Cl_2 :Acetone) to afford **26c** as a colorless amorphous solid (6.0 mg, 35%, 28% over 3 steps): ^1H NMR (CD_2Cl_2 , 500 MHz) δ 8.69 (s, 1H), 8.67 (s, 1H), 7.84 (dd, $J = 8.6, 2.4$ Hz, 1H), 7.80 (d, $J = 2.4$ Hz, 1H), 7.29 (d, $J = 8.0$ Hz, 1H), 7.25 (t, $J = 7.9$ Hz, 1H), 7.03-7.01 (m, 2H), 6.87 (s, 1H), 6.87-6.83 (m, 1H), 4.96 (d, $J = 6.8$ Hz, 1H), 4.61-4.56 (m, 1H), 4.19 (t, $J = 4.0$ Hz, 1H), 3.89 (dd, $J = 6.8, 3.7$ Hz, 1H), 3.82 (s, 3H), 3.76 (s, 3H), 3.75 (s, 1H), 3.41 (s, 3H), 3.34 (s, 1H), 3.03 (d, $J = 4.5$ Hz, 1H), 2.36 (s, 3H), 1.33 (t, $J = 6.2$ Hz, 6H), 1.25 (s, 3H), 1.23 (s, 3H); ^{13}C NMR (CD_2Cl_2 , 125 MHz) δ 164.6, 159.1, 158.6, 158.3, 146.7, 146.3, 142.5, 138.1, 130.2, 129.1, 128.3, 127.4, 125.2, 122.8, 122.2, 121.2, 121.1, 115.5, 144.5, 112.1, 110.2, 108.4, 101.4, 81.9, 77.0, 71.1, 69.2, 68.3, 59.1, 55.1, 54.5, 28.7, 28.6, 20.8, 20.8, 9.1; IR (film) ν_{max} 2924, 2854, 2359, 2341, 1734, 1684, 1653, 1558, 1541, 1522, 1506, 1458, 1387, 1339, 1286, 1244, 1113, 912, 797 cm^{-1} ; HRMS (ESI⁺) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{36}\text{H}_{41}\text{NO}_{11}$, 686.2578; found, 686.2610.

***N*-(7-((2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-5-methoxy-8-methyl-2-oxo-2*H*-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide (26d)**

Palladium on carbon (10%, 40 mg) was added to **25d** (200 mg, 0.36 mmol) in anhydrous THF (2.40 mL) and the solution was placed under an atmosphere of H_2 . After 12 h, the solution was filtered through SiO_2 (1:1 CH_2Cl_2 :Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (150 mg, 99%).

EDCI (57.5 mg, 0.30 mmol) and 3',6-dimethoxybiphenyl-3-carboxylic acid (62 mg, 0.24 mmol) were added to the amine (50.6 mg, 0.12 mmol) in 30% pyridine/ CH_2Cl_2 (3.30 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO_2 , 3:1 Hexane:Ether \rightarrow 40:1 \rightarrow 10:1 CH_2Cl_2 :Acetone) to afford a colorless solid, which was used without further purification (25.2 mg, 32%).

Triethylamine (150 μ L) was added to the carbonate (25.2 mg, 0.038 mmol) in MeOH (2.0 mL) and CH_2Cl_2 (2.0 mL). After 48 h, the solvent was concentrated and the residue purified via column chromatography (SiO_2 , 40:1 CH_2Cl_2 :Acetone) to afford **26d** as a colorless amorphous solid (17.0 mg, 70%, 22% over 3 steps): ^1H NMR (CD_2Cl_2 , 400 MHz) δ 9.02 (s, 1H), 8.97 (s, 1H), 8.66 (s, 1H), 7.96 (dd, $J = 8.6, 2.4$ Hz, 1H), 7.91-7.90 (m, 1H), 7.39 (t, $J = 7.9$ Hz, 1H), 7.16-7.11 (m, 2H), 6.96 (dd, $J = 8.3, 2.6$ Hz), 6.85 (d, $J = 5.5$ Hz, 1H), 5.70 (d, $J = 2.1$ Hz, 1H), 4.36-4.33 (m, 1H), 4.27 (m, 1H), 3.99 (s, 3H), 3.93 (s, 3H), 3.88 (s, 3H), 3.62 (s, 3H), 3.41-3.38 (m, 1H), 2.24 (s, 3H), 1.41 (s, 3H), 1.19 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 164.2, 158.7, 158.6, 158.3, 155.3, 153.5, 148.6, 137.6, 129.9, 128.9, 128.1, 127.1, 125.1, 121.0, 119.4, 118.9, 114.2, 114.2, 112.1, 110.0, 104.9, 103.7, 96.7, 92.9, 83.2, 70.1, 67.5, 60.9, 60.8, 54.8, 54.3, 21.9, 21.4, 6.8; IR (film) ν_{max} 3405, 2986, 2934, 1713, 1609, 1528, 1383, 1250, 1213, 1053, 999, 914, 878, 737 cm^{-1} ; HRMS (ESI⁺) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{34}\text{H}_{37}\text{NO}_{11}$, 636.2445; found, 636.2482.

***N*-(8-benzyl-7-((2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-2-oxo-2*H*-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide (26e)**

Palladium on carbon (10%, 46 mg) was added to **25e** (230 mg, 0.38 mmol) in anhydrous THF (2.50 mL) and the solution was placed under an atmosphere of H_2 . After 12 h, the solution was filtered through SiO_2 (1:1 CH_2Cl_2 :Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (177 mg, 99%).

EDCI (61.5 mg, 0.32 mmol) and 3',6-dimethoxybiphenyl-3-carboxylic acid (66.3 mg, 0.26 mmol) were added to the amine (60.0 mg, 0.13 mmol) in 30% pyridine/ CH_2Cl_2 (3.50 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO_2 , 3:1 Hexane:Ether \rightarrow 20:1 CH_2Cl_2 :Acetone) to afford a colorless solid, which was used without further purification (12.3 mg, 14%).

Triethylamine (150 μ L) was added to the carbonate (12.3 mg, 0.017 mmol) in MeOH (1.5 mL) and CH_2Cl_2 (1.5 mL). After 48 h, the solvent was concentrated and the residue purified via column chromatography (SiO_2 , 40:1 CH_2Cl_2 :Acetone) to afford **26e** as a colorless amorphous solid (6.00 mg, 51%, 7.1% over 3 steps): ^1H NMR (CD_2Cl_2 , 400 MHz) δ 8.84 (s, 1H), 8.72 (s, 1H), 7.96 (dd, $J = 10, 2.4$ Hz, 1H), 7.91 (d, $J = 2.4$ Hz, 1H), 7.50 (d, $J = 8.8$ Hz, 1H), 7.39 (t, $J = 7.9$ Hz, 1H), 7.31 (d, $J = 8.8$ Hz, 1H), 7.28-7.25 (m, 5H), 7.21-7.18 (m, 1H), 7.15-7.11 (m, 2H), 6.97-6.94 (m, 1H), 5.54 (d, $J = 2.7$ Hz, 1H), 4.25 (t, $J = 15.1$ Hz, 2H), 4.17-4.11 (m, 1H), 4.05 (d, $J = 2.6$ Hz, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 3.58 (s, 3H), 3.31 (d, $J = 8.7$ Hz, 1H), 2.64 (s, 1H), 2.04 (s, 1H), 1.40 (s, 3H), 1.03 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 165.5, 159.8, 159.3, 159.3, 156.4, 148.9, 140.0 (2C), 138.6, 131.1, 130.0, 129.2, 128.5, 128.3, 128.2, 127.0, 126.2 (2C), 126.0 (2C), 124.1, 122.2, 122.0, 117.2, 115.2, 114.4, 113.2, 111.7, 111.0, 98.0, 70.6 (2C), 68.6, 61.6, 55.9, 55.4, 29.3, 28.9, 28.3; IR (film) ν_{max} 3404, 2930, 2359, 2341, 1713, 1670, 1605, 1526, 1502, 1367, 1244, 1180, 1134, 1076, 1026, 960 cm^{-1} ; HRMS (ESI⁺) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{39}\text{H}_{39}\text{NO}_{10}$, 682.2652; found, 682.2653.

***N*-(7-((2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-2-oxo-8-phenyl-2*H*-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide (26f)**

Palladium on carbon (10%, 14 mg) was added to **25f** (68.0 mg, 0.12 mmol) in anhydrous THF (800 μ L) and the solution was placed under an atmosphere of H_2 . After 12 h, the solution was filtered through SiO_2 (1:1 CH_2Cl_2 :Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (52.0 mg, 99%).

EDCI (18.5 mg, 0.096 mmol) and 3',6-dimethoxybiphenyl-3-carboxylic acid (19.9 mg, 0.077 mmol) were added to the amine (17.5 mg, 0.039 mmol) in 30% pyridine/ CH_2Cl_2 (1.10 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography

(SiO₂, 40:1 CH₂Cl₂:Acetone) to afford a colorless solid, which was used without further purification (14.0 mg, 52%).

Triethylamine (150 μ L) was added to the carbonate (14.0 mg, 0.020 mmol) in MeOH (1.5 mL) and CH₂Cl₂ (1.5 mL). After 48 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford **26f** as a colorless amorphous solid (5.20 mg, 39%, 20% over 3 steps): ¹H NMR (CD₂Cl₂, 500 MHz) δ 8.85 (s, 1H), 8.65 (s, 1H), 7.92 (d, *J* = 2.4 Hz, 1H), 7.90 (d, *J* = 2.4 Hz, 1H), 7.86 (d, *J* = 2.4 Hz, 1H), 7.57-7.43 (m, 3H), 7.36-7.33 (m, 4H), 7.11-7.06 (m, 3H), 6.92 (d, *J* = 0.8 Hz, 1H), 5.52 (d, *J* = 2.4 Hz, 1H), 4.08 (q, *J* = 7.2 Hz, 1H), 3.89 (s, 3H), 3.83 (s, 3H), 3.74 (dd, *J* = 9.0, 3.5 Hz, 1H), 3.50 (s, 3H), 3.23 (d, *J* = 9.0 Hz, 1H), 2.12 (s, 1H), 2.00 (s, 1H), 1.33 (s, 3H), 1.04 (s, 3H); ¹³C NMR (CD₂Cl₂, 125 MHz) δ 164.5, 159.0 (2C), 158.6, 158.1, 154.4, 147.2, 138.0 (2C), 130.7, 130.1, 129.7, 129.1, 128.7, 128.3, 127.4, 127.2, 127.0, 127.0, 125.2, 122.6, 121.6, 121.1, 118.6, 114.5, 113.8, 112.1, 111.3, 110.2, 97.5, 70.1 (2C), 67.4, 60.8, 55.0, 54.5, 21.9, 21.6; IR (film) ν_{\max} 3402, 2932, 2359, 2341, 1713, 1603, 1524, 1500, 1367, 1267, 1086, 1040, 964, 750 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₃₈H₃₇NO₁₀, 668.2496; found, 668.2485.

***N*-(7-((2*S*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-8-methoxy-2-oxo-2*H*-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide (26g)**

Palladium on carbon (10%, 47 mg) was added to **25g** (237 mg, 0.44 mmol) in anhydrous THF (2.93 mL) and the solution was placed under an atmosphere of H₂. After 12 h, the solution was filtered through SiO₂ (1:1 CH₂Cl₂:Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (177 mg, 99%).

EDCI (69.4 mg, 0.36 mmol) and 3',6-dimethoxybiphenyl-3-carboxylic acid (74.8 mg, 0.29 mmol) were added to the amine (59.0 mg, 0.14 mmol) in 30% pyridine/CH₂Cl₂ (4.00 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 3:1 Hexane:Ether \rightarrow 40:1 CH₂Cl₂:Acetone) to afford a colorless solid, which was used without further purification (26.0 mg, 28%).

Triethylamine (150 μ L) was added to the carbonate (26.0 mg, 0.040 mmol) in MeOH (2.0 mL) and CH₂Cl₂ (2.0 mL). After 48 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford **26g** as a colorless amorphous solid (15.7 mg, 63%, 18% over 3 steps): ¹H NMR (CD₂Cl₂, 400 MHz) δ 8.82 (s, 1H), 8.73 (s, 1H), 7.96 (dd, *J* = 8.6, 2.4 Hz, 1H), 7.91 (d, *J* = 2.4 Hz, 1H), 7.39 (t, *J* = 7.9 Hz, 1H), 7.30 (s, 2H), 7.14 (d, *J* = 8.6 Hz, 2H), 7.12 (d, *J* = 2.2 Hz, 1H), 6.96 (dd, *J* = 8.3, 2.5 Hz, 1H), 5.61 (d, *J* = 2.4 Hz, 1H), 4.29 (t, *J* = 4.0 Hz, 1H), 4.27-4.25 (m, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.88 (s, 3H), 3.62 (s, 3H), 3.47 (s, 1H), 3.37 (d, *J* = 8.8 Hz, 1H), 2.62 (s, 1H), 1.30 (s, 3H), 1.24 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 164.5, 158.8, 158.3, 157.8, 150.2 (2C), 142.9, 137.5, 135.6, 130.0, 128.9, 128.2, 127.2, 127.2, 124.9, 122.8, 121.6, 121.0, 114.3, 114.2, 112.3, 112.1, 110.0, 97.7, 70.0 (2C), 67.5, 60.8 (2C), 54.9, 54.3, 28.7, 28.3; IR (film) ν_{\max} 3402, 2961, 2928, 2853, 1713, 1672, 1607, 1526, 1504, 1462, 1367, 1263, 1248, 1086, 1040, 953, 798, 735, 700 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₃₃H₃₅NO₁₁, 622.2288; found, 622.2307.

***N*-(7-((2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-8-ethyl-2-oxo-2*H*-chromen-3-yl)-3',6-dimethoxybiphenyl-3-carboxamide (26h)**

Palladium on carbon (10%, 12 mg) was added to **25h** (121 mg, 0.22 mmol) in anhydrous THF (5.00 mL) and the solution was placed under an atmosphere of H₂. After 12 h, the solution was filtered through SiO₂ (1:1 CH₂Cl₂:Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (90.0 mg, 99%).

EDCI (46.2 mg, 0.24 mmol) and 3',6-dimethoxybiphenyl-3-carboxylic acid (43.9 mg, 0.19 mmol) were added to the amine (39.0 mg, 0.096 mmol) in 30% pyridine/CH₂Cl₂ (2.65 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford a colorless solid, which was used without further purification (39.1 mg, 66%).

Triethylamine (150 μL) was added to the carbonate (13.0 mg, 0.020 mmol) in MeOH (1.5 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 ¹H CH₂Cl₂:Acetone) to afford **26h** as a colorless amorphous solid (4.10 mg, 33%, 22% over 3 steps): ¹H NMR (CD₂Cl₂, 500 MHz) δ 8.70 (s, 1H), 8.61 (s, 1H), 7.83 (dd, *J* = 8.5, 2.5 Hz, 1H), 7.78 (d, *J* = 2.5 Hz, 1H), 7.31 (d, *J* = 9.0 Hz, 1H), 7.27 (t, *J* = 7.8 Hz, 1H), 7.17 (d, *J* = 8.5 Hz, 1H), 7.03-6.99 (m, 3H), 6.85-6.82 (m, 1H), 5.49 (d, *J* = 1.5 Hz, 1H), 4.15 (t, *J* = 8.5 Hz, 1H), 4.14 (d, *J* = 8.5 Hz, 1H), 3.90 (s, 2H), 3.87 (s, 3H), 3.81 (s, 3H), 3.28 (s, 3H), 3.27 (d, *J* = 8.5 Hz, 1H), 2.76 (q, *J* = 4.5 Hz, 2H), 1.29 (s, 3H), 1.09 (t, *J* = 7.4 Hz, 3H), 1.08 (s, 3H); ¹³C NMR (CD₂Cl₂, 125 MHz) δ 164.5, 159.0, 158.6, 158.5, 155.1, 147.9, 138.1, 130.1, 129.1, 128.3, 127.4, 125.4, 125.2, 123.1, 121.4, 121.2, 119.4, 114.5, 113.5, 112.1, 110.8, 110.2, 97.6, 83.4, 77.7, 70.6, 67.8, 61.0, 55.1, 54.5, 28.2, 21.6, 15.6, 12.9; IR (film) ν_{max} 3404, 2968, 2934, 2359, 2341, 1715, 1605, 1524, 1504, 1367, 1244, 1101, 1024, 995, 960, 800 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₃₄H₃₇NO₁₀, 620.2496; found, 620.2507.

***N*-(7-((2*S*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-6-methoxy-8-methyl-2-oxo-2*H*-chromen-3-yl)-1*H*-indole-2-carboxamide (26i)**

Palladium on carbon (10%, 15 mg) was added to **25a** (74.0 mg, 0.13 mmol) in anhydrous THF (5.00 mL) and the solution was placed under an atmosphere of H₂. After 12 h, the solution was filtered through SiO₂ (1:1 CH₂Cl₂:Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (60.0 mg, 99%).

EDCI (69.0 mg, 0.36 mmol) and 1*H*-indole-2-carboxylic acid (46.4 mg, 0.29 mmol) were added to the amine (60.0 mg, 0.14 mmol) in 30% pyridine/CH₂Cl₂ (3.50 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 3:1 Hexane:Ether → 40:1 CH₂Cl₂:Acetone) to afford a colorless solid, which was used without further purification (68.0 mg, 85%).

Triethylamine (150 μL) was added to the carbonate (68.0 mg, 0.12 mmol) in MeOH (2.5 mL) and CH₂Cl₂ (2.50 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford **26i** as a colorless amorphous solid (12.6 mg, 19%, 16% over 3 steps): ¹H NMR (CD₂Cl₂, 400 MHz) δ 8.29 (s, 1H), 7.63 (s, 1H), 7.45-7.39 (m, 3H), 6.92 (s, 1H), 6.85 (s, 1H), 6.19 (s, 1H), 5.09 (d, *J* = 6.5 Hz, 1H), 4.31-4.28 (m, 1H), 4.01-3.97 (m, 1H), 3.94 (s, 3H), 3.62 (s, 1H), 3.56 (s, 3H), 3.15 (d, *J* = 4.9 Hz, 1H), 2.46 (s, 3H), 2.36 (s, 1H), 1.38 (d, *J* = 11.5 Hz, 3H), 1.32 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 157.6, 152.1, 148.2, 145.4, 142.2, 134.5, 129.9, 127.8, 127.7, 127.5, 127.3, 122.3, 121.2, 120.2, 115.0, 105.3, 105.1, 101.3, 81.7, 69.0, 68.0, 66.5, 59.1, 55.2, 28.7, 24.6, 24.1, 9.1; IR (film) ν_{max} 2926, 1707, 1526, 1464, 1391, 1340, 1296, 1231, 1207, 1086, 1024, 943, 739, 700, 623 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + Na]⁺ calcd for C₂₈H₃₀N₂O₉, 561.1849; found, 561.1781.

***N*-(7-((2*S*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-8-methyl-2-oxo-6-propoxy-2*H*-chromen-3-yl)-1*H*-indole-2-carboxamide (26j)**

Palladium on carbon (10%, 85 mg) was added to **25b** (425 mg, 0.729 mmol) in anhydrous THF (4.90 mL) and the solution was placed under an atmosphere of H₂. After 12 h, the solution was filtered through SiO₂ (1:1 CH₂Cl₂:Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (325 mg, 99%).

EDCI (116 mg, 0.6026 mmol) and *1H*-indole-2-carboxylic acid (77.7 mg, 0.4821 mmol) were added to the amine (108 mg, 0.2410 mmol) in 30% pyridine/CH₂Cl₂ (6.70 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 3:1 Hexane:Ether → 40:1 CH₂Cl₂:Acetone) to afford a colorless solid, which was used without further purification (91.0 mg, 64%).

Triethylamine (150 μL) was added to the carbonate (91.0 mg, 0.1536 mmol) in MeOH (2.5 mL) and CH₂Cl₂ (2.50 mL). After 48 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford **26j** as a colorless amorphous solid (17.5 mg, 20%, 13% over 3 steps): ¹H NMR (CD₂Cl₂, 400 MHz) δ 9.32 (s, 1H), 8.80 (s, 1H), 8.76 (s, 1H), 7.77 (d, *J* = 8.0 Hz, 1H), 7.53 (d, *J* = 7.5 Hz, 1H), 7.40-7.36 (m, 1H), 7.24-7.20 (m, 1H), 6.98 (s, 1H), 6.01 (s, 1H), 5.15 (d, *J* = 6.5 Hz, 1H), 4.32-4.25 (m, 1H), 4.11-4.04 (m, 1H), 3.62-3.59 (m, 2H), 3.53 (s, 3H), 3.18-3.12 (m, 1H), 2.64 (s, 1H), 2.49 (s, 3H), 2.18 (s, 1H), 1.95-1.91 (m, 2H), 1.36 (d, *J* = 9.6 Hz, 3H), 1.29 (d, *J* = 9.8 Hz, 3H), 1.12 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 160.1, 159.0, 148.8, 146.9, 143.4, 136.9, 129.8, 127.6, 125.5, 123.5, 123.0, 122.6, 122.3, 121.2, 116.0, 112.0, 107.3, 104.3, 102.2, 82.8, 71.0, 70.1, 69.1, 60.2, 59.7, 25.7, 23.1, 23.4, 10.5, 10.2; IR (film) ν_{max} 3630, 3304, 2926, 2854, 2359, 2332, 1713, 1705, 1539, 1387, 1240, 1103, 947, 930, 822, 739 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₃₀H₃₄N₂O₉, 567.2342; found, 567.2367.

***N*-(7-((2*S*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-6-isopropoxy-8-methyl-2-oxo-2*H*-chromen-3-yl)-1*H*-indole-2-carboxamide (26k)**

Palladium on carbon (10%, 4 mg) was added to **25c** (19.0 mg, 0.033 mmol) in anhydrous THF (220 μL) and the solution was placed under an atmosphere of H₂. After 12 h, the solution was filtered through SiO₂ (1:1 CH₂Cl₂:Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (14.5 mg, 99%).

EDCI (15.6 mg, 0.081 mmol) and *1H*-indole-2-carboxylic acid (10.5 mg, 0.065 mmol) was added to the amine (14.5 mg, 0.033 mmol) in 30% pyridine/CH₂Cl₂ (1.00 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford a colorless solid, which was used without further purification (10.0 mg, 50%).

Triethylamine (150 μL) was added to the carbonate (10.0 mg, 0.017 mmol) in MeOH (2.5 mL) and CH₂Cl₂ (2.50 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 10:1 CH₂Cl₂:Acetone) to afford **26k** as a colorless amorphous solid (6.00 mg, 46%, 23% over 3 steps): ¹H NMR (CDCl₃, 500 MHz) δ 8.16 (s, 1H), 7.52 (s, 1H), 7.34-7.30 (m, 5H), 6.75 (s, 1H), 4.93 (d, *J* = 5.0 Hz, 1H), 4.56-4.51 (m, 1H), 4.23 (t, *J* = 4.0 Hz, 1H), 3.98-3.96 (m, 1H), 3.76 (s, 1H), 3.43 (s, 3H), 3.06 (d, *J* = 4.3 Hz, 1H), 2.65 (s, 1H), 2.38 (s, 3H), 1.33 (dd, *J* = 11.2, 6.1 Hz, 6H), 1.29 (s, 3H), 1.27 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 157.6, 152.1, 146.6, 146.0, 142.1, 134.5, 127.7, 127.5, 127.2, 122.2, 121.3 (2C), 120.2 (2C), 115.0 (2C), 108.1 (2C), 101.2, 81.6, 71.2, 68.9, 68.1, 66.5, 59.0, 24.8, 23.6, 20.8 (2C), 9.1; IR (film) ν_{max} cm⁻¹ 3406, 2930, 2375, 1705, 1522, 1394, 1229, 1205, 1111, 1078, 1049, 933, 793, 739, 698; HRMS (ESI⁺) *m/z*: [M + Na]⁺ calcd for C₃₀H₃₄N₂O₉, 589.2162; found, 589.2111.

***N*-(7-((2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-5-methoxy-8-methyl-2-oxo-2*H*-chromen-3-yl)-1*H*-indole-2-carboxamide (26l)**

Palladium on carbon (10%, 40 mg) was added to **25d** (200 mg, 0.36 mmol) in anhydrous THF (2.40 mL) and the solution was placed under an atmosphere of H₂. After 12 h, the solution was filtered through SiO₂ (1:1 CH₂Cl₂:Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (150 mg, 99%).

EDCI (57.5 mg, 0.30 mmol) and *1H*-indole-2-carboxylic acid (38.7 mg, 0.24 mmol) were added to the amine (50.6 mg, 0.12 mmol) in 30% pyridine/CH₂Cl₂ (3.30 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford a colorless solid, which was used without further purification (26.3 mg, 39%).

Triethylamine (150 μL) was added to the carbonate (26.3 mg, 0.047 mmol) in MeOH (2.00 mL) and CH₂Cl₂ (2.00 mL). After 48 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford **26l** as a colorless amorphous solid (6.60 mg, 26%, 10% over 3 steps): ¹H NMR (CD₂Cl₂, 400 MHz) δ 9.26 (s, 1H), 8.96 (s, 1H), 8.68 (s, 1H), 7.74 (d, *J* = 8.1 Hz, 1H), 7.52 (d, *J* = 8.3 Hz, 1H), 7.38-7.34 (m, 1H), 7.22-7.16 (m, 1H), 6.84 (s, 1H), 6.00 (s, 1H), 5.65 (d, *J* = 1.7 Hz, 1H), 4.26-4.21 (m, 2H), 3.96 (s, 3H), 3.59 (s, 3H), 3.35 (d, *J* = 8.6 Hz, 1H), 2.25 (s, 3H), 1.53 (s, 3H), 1.20 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 165.1, 157.4, 156.5, 149.7, 136.7, 134.7, 127.7, 125.3, 122.5, 121.1, 120.0, 111.9, 104.6, 103.8, 97.7, 94.0, 84.3, 84.2, 82.6, 69.6, 69.1, 66.1, 62.2, 62.0, 59.7, 23.1, 22.7, 14.2; IR (film) ν_{max} 3389, 2924, 2853, 1697, 1605, 1535, 1460, 1340, 1211, 1101, 1088, 962, 729 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₂₈H₃₀N₂O₉, 539.2030; found, 539.2056.

***N*-(8-benzyl-7-((2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-2-oxo-2*H*-chromen-3-yl)-1*H*-indole-2-carboxamide (26m)**

Palladium on carbon (10%, 46 mg) was added to **25e** (230 mg, 0.38 mmol) in anhydrous THF (2.50 mL) and the solution was placed under an atmosphere of H₂. After 12 h, the solution was filtered through SiO₂ (1:1 CH₂Cl₂:Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (177 mg, 99%).

EDCI (61.5 mg, 0.32 mmol) and *1H*-indole-2-carboxylic acid (41.4 mg, 0.26 mmol) were added to the amine (60.0 mg, 0.13 mmol) in 30% pyridine/CH₂Cl₂ (3.50 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 3:1 Hexane:Ether → 40:1 CH₂Cl₂:Acetone) to afford a yellow solid, which was used without further purification (66.2 mg, 85%).

Triethylamine (150 μL) was added to the carbonate (66.2 mg, 0.11 mmol) in MeOH (2.50 mL) and CH₂Cl₂ (2.50 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford **26m** as a colorless amorphous solid (6.50 mg, 10%, 8.4% over 3 steps): ¹H NMR (CD₂Cl₂, 500 MHz) δ 8.68 (s, 1H), 8.62 (s, 1H), 7.63-7.61 (m, 1H), 7.47 (dd, *J* = 5.7, 3.3 Hz, 1H), 7.16-7.10 (m, 4H), 7.10-7.04 (m, 4H), 6.99 (t, *J* = 8.2 Hz, 1H), 6.74 (d, *J* = 8.0 Hz, 1H), 6.43 (dd, *J* = 8.1, 0.7 Hz, 1H), 5.31 (d, *J* = 2.9 Hz, 1H), 4.17 (t, *J* = 6.8 Hz, 1H), 4.01 (dd, *J* = 8.5, 2.9 Hz, 1H), 3.90 (d, *J* = 13.1 Hz, 2H), 3.45 (s, 3H), 3.16 (d, *J* = 8.6 Hz, 1H), 2.43 (s, 1H), 2.21 (s, 1H), 1.25 (s, 3H), 0.95 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 166.8, 155.4, 153.8, 140.2, 131.6, 45 130.2, 128.0, 127.6, 127.5 (2C), 127.4 (2C), 126.9, 125.1 (2C), 115.2, 108.3 (2C), 105.8 (2C), 97.1 (2C), 83.3 (2C), 77.2, 70.2, 67.9 (2C), 65.0, 60.6, 21.9, 13.1, 13.0; IR (film) ν_{max} 3333, 2961, 2926, 2854, 1717, 1601, 1466, 1261, 1090, 1076, 1041, 800, 750 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + Na]⁺ calcd for C₃₃H₃₂N₂O₈, 607.2056; found, 607.2056.

***N*-(7-((2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-2-oxo-8-phenyl-2*H*-chromen-3-yl)-1*H*-indole-2-carboxamide (26n)**

Palladium on carbon (10%, 14 mg) was added to **25f** (68.0 mg, 0.12 mmol) in anhydrous THF (800 μL) and the solution was placed under an atmosphere of H₂. After 12 h, the solution was filtered through SiO₂ (1:1 CH₂Cl₂:Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (52.0 mg, 99%).

EDCI (18.5 mg, 0.096 mmol) and *1H*-indole-2-carboxylic acid (12.4 mg, 0.077 mmol) were added to the amine (17.5 mg, 0.039 mmol) in 30% pyridine/CH₂Cl₂ (1.10 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford a colorless solid, which was used without further purification (8.20 mg, 36%).

Triethylamine (150 μL) was added to the carbonate (8.2 mg, 0.014 mmol) in MeOH (1.00 mL) and CH₂Cl₂ (1.00 mL). After 48 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford **26n** as a colorless amorphous solid (4.00 mg, 51%, 18% over 3 steps): ¹H NMR (CD₂Cl₂, 500 MHz) δ 9.23 (s, 1H), 8.80 (s, 1H), 8.67 (s, 1H), 7.71 (dd, *J* = 8.0, 0.7 Hz, 1H), 7.57 (d, *J* = 8.8 Hz, 1H), 7.51-7.48 (m, 3H), 7.46-7.44 (m, 1H), 7.37-7.32 (m, 4H), 7.19-7.17 (m, 2H), 5.53 (d, *J* = 2.4 Hz, 1H), 3.86 (s, 1H), 3.76-3.73 (m, 2H), 3.51 (s, 3H), 3.23 (d, *J* = 9.1 Hz, 1H), 2.41 (s, 1H), 1.34 (s, 3H), 1.05 (s, 3H); ¹³C NMR (CD₂Cl₂, 125 MHz) δ 159.1, 157.9, 154.5, 147.3, 136.0 (2C), 130.7 (2C), 129.8, 129.2, 127.3, 127.1, 127.0, 126.9, 124.5, 122.8, 121.6, 121.2, 120.3, 113.7, 111.4, 111.1, 103.1 (2C), 97.5, 83.2, 77.7, 70.1, 67.5, 60.8, 21.9, 21.7; IR (film) ν_{max} 3427, 2961, 2924, 2853, 2062, 1643, 1614, 1537, 1362, 1236, 1094, 1041, 962, 791, 739, 698 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + Na]⁺ calcd for C₃₂H₃₀N₂O₈, 593.1900; found, 593.1890.

***N*-(7-((2*S*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-8-methoxy-2-oxo-2*H*-chromen-3-yl)-1*H*-indole-2-carboxamide (26o)**

Palladium on carbon (10%, 47 mg) was added to **25g** (237 mg, 0.44 mmol) in anhydrous THF (2.93 mL) and the solution was placed under an atmosphere of H₂. After 12 h, the solution was filtered through SiO₂ (1:1 CH₂Cl₂:Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (177 mg, 99%).

EDCI (69.4 mg, 0.36 mmol) and *1H*-indole-2-carboxylic acid (46.7 mg, 0.29 mmol) were added to the amine (59.0 mg, 0.14 mmol) in 30% pyridine/CH₂Cl₂ (4.00 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 3:1 Hexane:Ether → 40:1 CH₂Cl₂:Acetone) to afford a colorless solid, which was used without further purification (32.0 mg, 49%).

Triethylamine (150 μL) was added to the carbonate (32.0 mg, 0.071 mmol) in MeOH (2.00 mL) and CH₂Cl₂ (2.00 mL). After 48 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 3:1 CH₂Cl₂:Acetone) to afford **26o** as a colorless amorphous solid (22.1 mg, 73%, 35% over 3 steps): ¹H NMR (CD₂Cl₂, 400 MHz) δ 9.28 (s, 1H), 8.78 (s, 1H), 7.77 (d, *J* = 8.1 Hz, 1H), 7.53 (dd, *J* = 8.3, 0.8 Hz, 1H), 7.38 (m, 1H), 7.31 (s, 2H), 7.24 (d, *J* = 0.9 Hz, 1H), 7.22-7.20 (m, 1H), 6.02 (s, 1H), 5.62 (d, *J* = 2.3 Hz, 1H), 4.25 (t, *J* = 3.5 Hz, 1H), 3.99 (s, 3H), 3.75 (dd, *J* = 9.0, 3.6 Hz, 1H), 3.62 (s, 3H), 3.13 (d, *J* = 3.6 Hz, 1H), 1.30 (s, 3H), 1.27 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 163.8, 159.1, 157.7, 150.6, 143.3, 136.0, 135.8, 129.2, 126.9, 124.6, 122.8, 121.8, 121.6, 121.4, 120.3, 114.4, 112.5, 111.2, 103.1, 98.0, 83.2, 77.9, 74.0, 60.9, 58.7, 22.3, 21.8; IR (film) ν_{max} 3420, 2957, 2924, 2854, 2359, 1653, 1558, 1541, 1246, 1001, 798 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₂₇H₂₈N₂O₉, 525.1873; found, 525.1875.

***N*-(7-((2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2*H*-pyran-2-yloxy)-8-ethyl-2-oxo-2*H*-chromen-3-yl)-1*H*-indole-2-carboxamide (26p)**

Palladium on carbon (10%, 12 mg) was added to **25h** (121 mg, 0.22 mmol) in anhydrous THF (5.00 mL) and the solution was placed under an atmosphere of H₂. After 12 h, the solution was filtered through SiO₂ (1:1 CH₂Cl₂:Acetone) and the eluent was concentrated to afford a yellow solid, which was used without further purification (90.0 mg, 99%).

EDCI (28.3 mg, 0.15 mmol) and *1H*-indole-2-carboxylic acid (19.0 mg, 0.12 mmol) were added to the amine (24.0 mg, 0.059 mmol) in 30% pyridine/CH₂Cl₂ (1.63 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford a colorless foam, which was used without further purification (23.8 mg, 73%).

Triethylamine (150 μL) was added to the carbonate (14.1 mg, 0.026 mmol) in MeOH (1.50 mL). After 12 h, the solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 CH₂Cl₂:Acetone) to afford **26p** as a yellow amorphous solid (5.00 mg, 37%, 27% over 3 steps): ¹H NMR (CD₂Cl₂, 500 MHz) δ 8.65 (s, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.41 (d, *J* = 8.5 Hz, 1H), 7.33 (d, *J* = 8.5 Hz, 1H), 7.23 (t, *J* = 7.8 Hz, 1H), 7.20 (d, *J* = 8.5 Hz, 2H), 7.13 (s, 2H), 7.07 (t, *J* = 7.5 Hz, 1H), 5.46 (d, *J* = 2.0 Hz, 1H), 4.07 (dd, *J* = 9.3, 3.5 Hz, 1H), 4.04 (t, *J* = 3.5 Hz, 1H), 3.51 (s, 3H), 3.25 (d, *J* = 7.2 Hz, 1H), 2.78 (q, *J* = 7.0 Hz, 2H), 1.27 (s, 3H), 1.10 (t, *J* = 7.5 Hz, 3H), 1.06 (s, 3H); ¹³C NMR (CD₂Cl₂, 125 MHz) δ 158.4, 157.3, 154.2, 146.8, 135.3, 128.1, 125.5, 124.0, 123.0, 123.0, 122.8, 120.1, 119.5, 118.7, 118.2, 112.0, 110.1, 109.7, 102.4, 97.0, 82.1, 76.5, 69.3, 66.4, 26.7, 20.3, 14.3, 11.4; IR (film) ν_{max} 3435, 3416, 2974, 2935, 2469, 2359, 2339, 1715, 1651, 1520, 1456, 1435, 1379, 1354, 1259, 1180, 1113, 1088, 1026, 997, 962, 798, 739 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + Na]⁺ calcd for C₂₈H₃₀N₂O₈, 545.1900; found, 545.1909.

***tert*-Butyl quinolin-7-yl carbonate (28)**

Di-*tert*-butyl dicarbonate (7.40 g, 33.92 mmol) and 4-(dimethylamino)pyridine (222 mg, 1.81 mmol) were added in sequence to 7-hydroxyquinoline (2.00 g, 13.75 mmol) in anhydrous *N,N*-dimethylformamide (20.0 mL) at rt. After 18 h, the reaction was diluted with EtOAc (250 mL). The organic layer was washed with 1.0 M NaOH (250 mL), water (3 × 250 mL), saturated aqueous NaCl solution (250 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 1:1 Hexanes:EtOAc) to give **28** as a colorless amorphous solid (3.26 g, 97%): ¹H NMR (CDCl₃, 500 MHz) δ 8.93 (dd, *J* = 4.2, 1.7 Hz, 1H), 8.17 (bd, *J* = 8.4 Hz, 1H), 7.90 (d, *J* = 2.2 Hz, 1H), 7.84 (d, *J* = 8.9 Hz, 1H), 7.43 (dd, *J* = 8.8, 2.3 Hz, 1H), 7.40 (dd, *J* = 8.3, 4.3 Hz, 1H), 1.60 (s, 9H); ¹³C NMR (CDCl₃, 125 MHz) δ 151.7, 151.7, 148.9, 135.9, 129.0, 126.3, 122.0, 121.0, 120.2, 84.2, 27.8 (3C); IR (film) ν_{max} 1759, 1277, 1240, 1142, 768, 750 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₁₄H₁₅NO₃, 246.1130; found, 246.1113.

***N*-(4-Methoxybenzyl)-7-(benzyloxy)quinolin-3-amine (31)**

Bromine (790 μL, 2.48 g, 15.38 mmol) was added to **28** (3.26 g, 13.30 mmol) in CCl₄ (30.0 mL) at rt. This solution was heated to reflux, anhydrous pyridine (1.20 mL, 1.17 g, 14.84 mmol) was added over 10 min, and the solution was stirred at reflux for 18 h. The cooled reaction was diluted with EtOAc/MeOH (250 mL) and saturated aqueous NaHCO₃ (200 mL), then extracted with EtOAc (4 × 250 mL). Combined organic layers were dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 4:1 Hexanes:EtOAc) to give **29** as a light yellow solid containing >80% 3-bromo isomer (2.00 g, 46%), which was used without further purification.

Hydrogen chloride was bubbled through **29** (2.00 g, 6.16 mmol) in anhydrous MeOH (44.0 mL) for 3 min at rt, then the solution was stirred at 50° C for 5 min. The solvent was concentrated and the residue placed under high vacuum for 6 h to ensure complete removal of MeOH. The yellow residue was dissolved in anhydrous dimethylformamide (44.0 mL) and cooled to 0° C, then NaH (997 mg, 24.93 mmol) was added. After 15 min, BnBr (1.20 mL, 1.73 g, 10.09 mmol) was added and the reaction was warmed to rt over 18 h. Reaction contents were partitioned between saturated aqueous NaHCO₃ (500 mL) and EtOAc (500 mL), then extracted with EtOAc (3 × 500 mL). The combined organic layers were washed with water (3 × 1 L), saturated

aqueous NaCl solution (1 L), dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 9:1 Hexanes:EtOAc) to give **30** as a light orange solid containing >80% 3-bromo isomer (1.70 g, 88%), which was used without further purification.

4-Methoxy-benzylamine (1.77 mL, 1.87 g, 13.64 mmol) and anhydrous DMSO (2.90 mL) were added to a high-pressure flask charged with **30** (1.65 g, 5.26 mmol), K₃PO₄ (2.36 g, 11.10 mmol), Cu^I (167 mg, 0.88 mmol), and *L*-(-)-proline (141 mg, 1.22 mmol); the sealed flask was heated to 80° C for 44 h. After cooling to rt, reaction contents were partitioned between water (50 mL) and EtOAc (100 mL), then were extracted with EtOAc (2 × 100 mL). The combined organic layers were washed with saturated aqueous NaCl solution (200 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 1:1 Hexanes:EtOAc) to give **31** as a light yellow amorphous solid (1.43 g, 73%): ¹H NMR (CDCl₃, 500 MHz) δ 8.44 (d, *J* = 2.8 Hz, 1H), 7.52 (d, *J* = 8.9 Hz, 1H), 7.50 (m, 2H), 7.43-7.38 (m, 3H), 7.36-7.32 (m, 3H), 7.20 (dd, *J* = 8.9, 2.6 Hz, 1H), 7.06 (d, *J* = 2.7 Hz, 1H), 6.91 (m, 2H), 5.17 (s, 2H), 4.35 (d, *J* = 4.8 Hz, 2H), 4.17 (bt, *J* = 4.8 Hz, 1H), 3.82 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 159.3, 156.9, 143.4, 143.3, 140.5, 137.0, 130.6, 129.1 (2C), 128.8 (2C), 128.2, 127.9 (2C), 127.3, 124.7, 120.4, 114.4 (2C), 112.0, 109.0, 70.3, 55.5, 48.0; IR (film) ν_{max} 3279, 2953, 2833, 1609, 1510, 1377, 1354, 1302, 1225, 1175, 1124, 1028, 995, 868, 818, 762, 708 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₂₄H₂₂N₂O₂, 371.1759; found, 371.1732.

***N*-(4-Methoxybenzyl)-*N*-(7-(benzyloxy)quinolin-3-yl)-4-methoxy-3-(3-methoxyphenyl)-benzamide (32)**

Thionyl chloride (395 μL, 644 mg, 5.42 mmol) was added to 4-methoxy-3-(3-methoxyphenyl)-benzoic acid (464 mg, 1.80 mmol) in anhydrous THF (6.10 mL) at rt and the resulting solution was heated at reflux for 4.5 h. The solvent was removed and the resulting acid chloride was used without further purification.

Sodium hydride (93 mg, 2.31 mmol) was added to **31** (508 mg, 1.37 mmol) in anhydrous THF (9.10 mL). After stirring for 2 h at rt, a solution of the freshly-prepared acid chloride (1.80 mmol) in anhydrous THF (3.00 mL) was added and the reaction was heated to reflux for 18 h. The reaction was cooled, partitioned between saturated aqueous NaHCO₃ (50 mL) and CH₂Cl₂ (50 mL), then extracted with CH₂Cl₂ (3 × 100 mL). Combined organic extracts were washed with saturated aqueous NaCl solution (200 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 1:1 EtOAc:Hexanes to 2:1 EtOAc:Hexanes) to give **32** as a pale yellow amorphous solid (684 mg, 82%): ¹H NMR (CDCl₃, 500 MHz) δ 8.35 (d, *J* = 2.3 Hz, 1H), 7.67 (d, *J* = 2.4 Hz, 1H), 7.57 (d, *J* = 9.0 Hz, 1H), 7.48 (m, 2H), 7.44-7.34 (m, 5H), 7.29 (m, 2H), 7.23 (m, 2H), 7.13 (t, *J* = 7.9 Hz, 1H), 6.81 (m, 2H), 6.78 (dd, *J* = 2.5, 1.0 Hz, 1H), 6.74 (d, *J* = 8.6 Hz, 1H), 6.64 (m, 1H), 6.61 (m, 1H), 5.19 (s, 2H), 5.15 (s, 2H), 3.77 (s, 3H), 3.72 (s, 3H), 3.66 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.2, 160.2, 159.3, 159.3, 157.9, 150.9, 147.9, 138.9, 136.4, 136.0, 132.6, 132.4, 130.5, 130.2 (2C), 130.1, 129.4, 129.0, 129.0 (2C), 128.5, 127.9 (2C), 127.4, 123.1, 122.1, 121.2, 114.8, 114.2 (2C), 113.3, 110.6, 108.6, 70.5, 55.7, 55.4, 55.3, 53.8; IR (film) ν_{max} 3032, 3001, 2953, 2935, 2835, 1645, 1603, 1512, 1456, 1429, 1385, 1331, 1248, 1209, 1178, 1034, 1026, 818, 735, 698 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₃₉H₃₄N₂O₅, 611.2546; found, 611.2574.

***N*-(4-Methoxybenzyl)-*N*-(7-(hydroxy)quinolin-3-yl)-4-methoxy-3-(3-methoxyphenyl)-benzamide (33)**

A solution of AlCl₃ (44 mg, 0.33 mmol) in anhydrous anisole (150 μL) was added to **32** (43 mg, 0.07 mmol) in anhydrous anisole (150 μL) and the resulting solution was stirred at rt for

18 h. The reaction was diluted with MeOH (150 μ L) and the solvent was concentrated. The residue was purified via column chromatography (SiO₂, 80:20:1 EtOAc:Hexanes:MeOH) to give **33** as a yellow amorphous solid in quantitative yield: ¹H NMR (CDCl₃, 500 MHz) δ 8.35 (s, 1H), 7.74 (s, 1H), 7.58 (d, *J* = 8.9 Hz, 1H), 7.52 (bs, 1H), 7.37 (m, 1H), 7.31 (m, 1H), 7.25-7.11 (m, 5H), 6.84-6.77 (m, 3H), 6.74 (d, *J* = 8.6 Hz, 1H), 6.67 (d, *J* = 7.6 Hz, 1H), 6.64 (s, 1H), 5.16 (s, 2H), 3.76 (s, 3H), 3.70 (s, 3H), 3.68 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.3, 159.4, 159.3, 158.0, 138.8, 135.5, 132.3, 130.4, 130.3, 130.1 (2C), 129.6, 129.1 (2C), 127.1, 123.0, 122.0, 114.9, 114.3 (2C), 113.3, 110.7, 55.8, 55.4, 53.9; IR (film) ν_{\max} 2926, 1601, 1506, 1248, 1177, 1030, 818 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₃₂H₂₈N₂O₅, 521.2076; found, 521.2030.

***N*-(7-Hydroxyquinolin-3-yl)-4-methoxy-3-(3-methoxyphenyl)-benzamide (34)**

Trifluoromethanesulfonic acid (120 μ L, 204 mg, 1.36 mmol) was added to **32** (184 mg, 0.30 mmol) in 1:1 CH₂Cl₂:TFA (1.36 mL) and the solution was stirred at rt for 2 h. The resulting solution was diluted with CH₂Cl₂ (100 mL), washed with saturated aqueous NaHCO₃ (3 \times 50 mL), saturated aqueous NaCl solution (2 \times 50 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 100:1 EtOAc:MeOH to 4:1 EtOAc:MeOH) to give **34** as a yellow oil (51 mg, 43%): ¹H NMR (CD₃OD, 500 MHz) δ 9.01 (bs, 1H), 8.61 (bs, 1H), 8.02 (dd, *J* = 8.5, 1.7 Hz, 1H), 7.97 (d, *J* = 1.9 Hz, 1H), 7.74 (d, *J* = 8.9 Hz, 1H), 7.30 (t, *J* = 8.2 Hz, 1H), 7.27 (d, *J* = 1.9 Hz, 1H), 7.19 (dd, *J* = 8.9, 2.1 Hz, 1H), 7.17 (d, *J* = 8.8 Hz, 1H), 7.11-7.08 (m, 2H), 6.89 (m, 1H), 3.88 (s, 3H), 3.81 (s, 3H); ¹³C NMR (CD₃OD, 125 MHz) δ 168.7, 161.2, 160.9, 160.2, 147.1, 146.2, 140.5, 132.0, 132.0, 131.5, 130.4, 130.2, 130.1, 128.5, 127.6, 124.2, 123.2, 121.5, 116.5, 113.8, 112.4, 109.7, 56.5, 55.9; IR (film) ν_{\max} 3281, 3203, 2930, 2835, 1605, 1545, 1499, 1371, 1252, 1036, 764, 735 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₂₄H₂₀N₂O₄, 401.1501; found, 401.1481.

2-(Benzyloxy)-6-bromonaphthalene (36)

Sodium hydride (1.16 g, 29.12 mmol) was added to 6-bromo-2-naphthol (5.00 g, 22.41 mmol) in anhydrous *N,N*-dimethylformamide (162 mL) at 0° C. After 15 min, benzyl bromide (2.40 mL, 3.45 g, 20.18 mmol) was added and the reaction warmed to rt over 18 h. The reaction was diluted with EtOAc (500 mL), saturated aqueous NaHCO₃ (200 mL) was added, and the solution was extracted with EtOAc (3 \times 500 mL). The combined organic layers were washed with water (3 \times 1 L), saturated aqueous NaCl solution (1 L), dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 5:1 Hexanes:CH₂Cl₂) to give **36** as a colorless amorphous solid (5.71 g, 90%): ¹H NMR (CDCl₃, 500 MHz) δ 7.94 (d, *J* = 1.9 Hz, 1H), 7.68 (d, *J* = 9.0 Hz, 1H), 7.61 (d, *J* = 8.7 Hz, 1H), 7.53-7.47 (m, 3H), 7.46-7.40 (m, 2H), 7.37 (m, 1H), 7.26 (dd, *J* = 9.0, 2.5 Hz, 1H), 7.20 (d, *J* = 2.5 Hz, 1H), 5.18 (s, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 157.2, 136.8, 133.2, 130.3, 129.9, 129.9, 128.9 (2C), 128.8, 128.7, 128.4, 127.8 (2C), 120.3, 117.4, 107.3, 70.3; IR (film) ν_{\max} 1585, 1452, 1256, 1219, 1204, 1165, 1065, 997, 924, 852, 820, 800, 733, 698, 476 cm⁻¹.

***N*-(4-Methoxybenzyl)-6-(benzyloxy)naphthalen-2-amine (37)**

4-Methoxy-benzylamine (3.40 mL, 3.59 g, 26.20 mmol) and anhydrous DMSO (5.20 mL) were added to a high-pressure flask charged with **36** (3.00 g, 9.58 mmol), K₃PO₄ (4.19 g, 19.73 mmol), Cu^I (290 mg, 1.52 mmol), and *L*-(-)-proline (255 mg, 2.21 mmol); the sealed flask was heated to 80° C for 44 h. After cooling to rt, reaction contents were partitioned between water (100 mL) and EtOAc (200 mL), then were extracted with EtOAc (2 \times 200 mL). The combined organic layers were washed with saturated aqueous NaCl solution (500 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was purified via column chromatography (SiO₂, 7:1:1 Hexanes:CH₂Cl₂:EtOAc) to give **37** as a light orange amorphous solid (952 mg,

27%): ^1H NMR (CDCl_3 , 500 MHz) δ 7.55 (d, $J = 8.7$ Hz, 2H), 7.49 (m, 2H), 7.41 (m, 2H), 7.37-7.32 (m, 3H), 7.15 (dd, $J = 8.8, 2.6$ Hz, 1H), 7.13 (m, 1H), 6.92 (dd, $J = 8.8, 2.3$ Hz, 1H), 6.90 (d, $J = 8.7$ Hz, 2H), 6.87 (m, 1H), 5.14 (s, 2H), 4.35 (s, 2H), 3.82 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 159.1, 154.6, 137.4, 130.7, 129.3 (2C), 128.8 (2C), 128.1, 128.0, 127.8 (2C), 119.4 (2C), 118.6, 114.3 (2C), 107.9, 70.3, 55.5; IR (film) ν_{max} 3734, 1558, 1456, 1259, 1167, 847, 746, 702, 660 cm^{-1} ; HRMS (ESI $^+$) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{23}\text{NO}_2$, 370.1807; found, 370.1786.

***N*-(4-Methoxybenzyl)-*N*-(6-(benzyloxy)naphthalen-2-yl)-4-methoxy-3-(3-methoxyphenyl)-benzamide (38)**

Thionyl chloride (308 μL , 502 mg, 4.22 mmol) was added to 4-methoxy-3-(3-methoxyphenyl)-benzoic acid (365 mg, 1.41 mmol) in anhydrous THF (4.75 mL) at rt, and the resulting solution was heated at reflux for 4.5 h. The solvent was removed and the resulting acid chloride was used without further purification.

Sodium hydride (85 mg, 2.12 mmol) was added to **37** (378 mg, 1.02 mmol) in anhydrous THF (7.50 mL). After stirring for 2 h at rt, a solution of the freshly-prepared acid chloride (1.41 mmol) in anhydrous THF (2.40 mL) was added and the reaction was heated to reflux for 18 h. The reaction was cooled, partitioned between saturated aqueous NaHCO_3 (50 mL) and CH_2Cl_2 (50 mL), then extracted with CH_2Cl_2 (3 \times 100 mL). Combined organic extracts were washed with saturated aqueous NaCl solution (200 mL), dried (Na_2SO_4), filtered, and concentrated. The residue was purified via column chromatography (SiO_2 , 4:1:1 Hexanes:EtOAc: CH_2Cl_2) to give **38** as a brown-yellow amorphous solid (515 mg, 83%): ^1H NMR (CDCl_3 , 500 MHz) δ 7.58 (d, $J = 9.0$ Hz, 1H), 7.55 (d, $J = 8.7$ Hz, 1H), 7.50-7.45 (m, 3H), 7.44-7.40 (m, 2H), 7.38-7.34 (m, 2H), 7.29 (d, $J = 2.2$ Hz, 1H), 7.25 (m, 2H), 7.21 (dd, $J = 8.9, 2.6$ Hz, 1H), 7.15 (d, $J = 2.4$ Hz, 1H), 7.09 (m, 1H), 7.01 (dd, $J = 8.7, 2.1$ Hz, 1H), 6.80 (m, 2H), 6.77 (ddd, $J = 8.2, 2.7, 0.9$ Hz, 1H), 6.74 (d, $J = 8.7$ Hz, 1H), 6.59-6.56 (m, 2H), 5.16 (s, 2H), 5.14 (s, 2H), 3.78 (s, 3H), 3.72 (s, 3H), 3.62 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 170.0, 159.3, 159.0, 157.6, 157.3, 139.9, 139.1, 136.8, 133.0, 132.4, 130.5, 130.1, 130.1 (2C), 129.6, 129.5, 129.1, 128.9, 128.9 (2C), 128.4, 128.2, 127.9, 127.7 (2C), 127.3, 125.8, 122.1, 120.0, 114.7, 114.0 (2C), 113.2, 110.4, 107.1, 70.3, 55.7, 55.4, 55.2, 53.9; IR (film) ν_{max} 3059, 3032, 2999, 2934, 2835, 1636, 1601, 1506, 1456, 1389, 1248, 1209, 1026, 854, 818, 735, 698 cm^{-1} ; HRMS (ESI $^+$) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{40}\text{H}_{35}\text{NO}_5$, 610.2593; found, 610.2567.

***N*-(4-Methoxybenzyl)-*N*-(6-hydroxynaphthalen-2-yl)-4-methoxy-3-(3-methoxyphenyl)-benzamide (39)**

A solution of AlCl_3 (203 mg, 1.52 mmol) in anhydrous anisole (750 μL) was added to **38** (191 mg, 0.31 mmol) in anhydrous anisole (750 μL) and the resulting solution was stirred at rt for 18 h. The reaction was diluted with MeOH (750 μL) and the solvent was concentrated. The residue was purified via column chromatography (SiO_2 , 1:1 EtOAc:Hexanes) to give **39** as a light yellow amorphous solid (126 mg, 77%): ^1H NMR (CDCl_3 , 500 MHz) δ 7.56 (m, 1H), 7.50 (d, $J = 8.7$ Hz, 1H), 7.47 (dd, $J = 8.6, 2.3$ Hz, 1H), 7.36 (d, $J = 2.0$ Hz, 1H), 7.29 (d, $J = 2.2$ Hz, 1H), 7.25 (m, 2H), 7.12-7.06 (m, 3H), 7.00 (dd, $J = 8.7, 2.1$ Hz, 1H), 6.80 (m, 2H), 6.77 (m, 1H), 6.73 (d, $J = 8.7$ Hz, 1H), 6.59-6.55 (m, 2H), 5.43 (s, 1H), 5.15 (s, 2H), 3.77 (s, 3H), 3.71 (s, 3H), 3.62 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 170.2, 159.3, 159.0, 157.6, 154.2, 139.7, 139.0, 133.1, 132.4, 130.5, 130.1, 130.1 (2C), 130.0, 129.5, 128.9, 128.9, 128.0, 127.5, 127.3, 125.9, 122.1, 118.7, 114.7, 114.0 (2C), 113.2, 110.4, 109.5, 55.7, 55.4, 55.3, 54.0; IR (film) ν_{max} 3236, 2934, 2835, 1599, 1508, 1456, 1437, 1394, 1248, 1177, 1036 cm^{-1} ; HRMS (ESI $^+$) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{33}\text{H}_{29}\text{NO}_5$, 520.2124; found, 520.2120.

***N*-(4-Methoxybenzyl)-*N*-(7-((2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2*H*-pyran-2-yloxy)quinolin-3-yl)-4-methoxy-3-(3-methoxyphenyl)-benzamide (42a)**

Boron trifluoride etherate (45 μ L, 52 mg, 0.36 mmol) was added to **33** (160 mg, 0.31 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1.3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (181 mg, 0.50 mmol) in anhydrous CH₂Cl₂ (5.00 mL). After stirring at rt for 40 h, triethylamine (30 μ L) was added and the solvent was concentrated. The residue was partially purified via column chromatography (SiO₂, 1:1 EtOAc:Hexanes) to provide **41a**, which was used without further purification.

Carbonate **41a** was added to MeOH (22.0 mL), CH₂Cl₂ (1.5 mL), and triethylamine (2.2 mL) and stirred for 18 h at rt. The solvent was concentrated and the residue purified via column chromatography (SiO₂, 50:1 EtOAc:MeOH) to give **42a** as a near-colorless amorphous solid (33 mg, 16% over two steps): ¹H NMR (CDCl₃, 500 MHz) δ 8.38 (d, *J* = 2.4 Hz, 1H), 7.67 (d, *J* = 2.4 Hz, 1H), 7.65 (d, *J* = 2.3 Hz, 1H), 7.54 (d, *J* = 9.1 Hz, 1H), 7.41 (dd, *J* = 8.6, 2.3 Hz, 1H), 7.26 (d, *J* = 2.3 Hz, 1H), 7.22 (m, 2H), 7.17 (dd, *J* = 8.9, 2.4 Hz, 1H), 7.10 (t, *J* = 7.8 Hz, 1H), 6.80 (m, 2H), 6.75 (dd, *J* = 8.4, 1.0 Hz, 1H), 6.74 (d, *J* = 8.7 Hz, 1H), 6.62-6.57 (m, 2H), 5.69 (d, *J* = 2.3 Hz, 1H), 5.15 (AB, *J*_{AB} = 14.6 Hz, 1H), 5.15 (AB, *J*_{AB} = 14.6 Hz, 1H), 4.23 (dd, *J* = 9.1, 3.4 Hz, 1H), 4.15 (m, 1H), 3.76 (s, 3H), 3.70 (s, 3H), 3.64 (s, 3H), 3.59 (s, 3H), 3.38 (d, *J* = 9.1 Hz, 1H), 1.39 (s, 3H), 1.17 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.3, 159.3, 159.2, 158.1, 157.9, 150.9, 147.4, 138.8, 136.1, 132.7, 132.4, 130.5, 130.1 (2C), 129.3, 129.0, 128.9, 127.3, 123.4, 122.0, 120.7, 114.8, 114.2 (2C), 113.2, 111.3, 110.7, 98.2, 84.5, 78.7, 71.1, 68.6, 62.0, 55.7, 55.4, 55.3, 53.8, 29.0, 23.0; IR (film) ν_{max} 2937, 2833, 1601, 1246, 1209, 1117, 1033, 989, 964 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₄₀H₄₂N₂O₉, 695.2969; found, 695.2891.

***N*-(7-((2*R*,3*R*,4*S*,5*R*)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2*H*-pyran-2-yloxy)quinolin-3-yl)-4-methoxy-3-(3-methoxyphenyl)-benzamide (42b)**

Boron trifluoride etherate (46 μ L, 53 mg, 0.37 mmol) was added to **34** (51 mg, 0.13 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1.3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (180 mg, 0.50 mmol) in anhydrous CH₂Cl₂ (5.00 mL). After stirring at rt for 40 h, triethylamine (30 μ L) was added and the solvent was concentrated. The residue was purified via column chromatography (SiO₂, 1:1 EtOAc:Hexanes) to give **41b** (29 mg, 37%) in a 10:1 ratio of anomers (α : β), which was used without further purification.

Carbonate **41b** was added to MeOH (7.5 mL), CH₂Cl₂ (500 μ L), and triethylamine (750 μ L) and stirred for 18 h at rt. The solvent was concentrated and the residue purified via column chromatography (SiO₂, 40:1 EtOAc:MeOH) to give **42b** as a near-colorless amorphous solid (11 mg, 15% over two steps): ¹H NMR (CDCl₃, 500 MHz) δ 8.81 (bs, 2H), 7.98 (dd, *J* = 8.7, 2.4 Hz, 1H), 7.89 (d, *J* = 2.3 Hz, 1H), 7.72 (d, *J* = 9.0 Hz, 1H), 7.70 (d, *J* = 1.9 Hz, 1H), 7.37 (t, *J* = 8.0 Hz, 1H), 7.23 (dd, *J* = 9.0, 2.3 Hz, 1H), 7.13 (dt, *J* = 7.8, 1.2 Hz, 1H), 7.10 (m, 1H), 7.09 (d, *J* = 8.6 Hz, 1H), 6.94 (ddd, *J* = 8.2, 2.5, 0.8 Hz, 1H), 5.73 (d, *J* = 2.0 Hz, 1H), 4.30-4.22 (m, 2H), 3.91 (s, 2H), 3.86 (s, 3H), 3.61 (s, 3H), 3.39 (d, *J* = 8.9 Hz, 1H), 1.40 (s, 3H), 1.21 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 165.8, 159.9, 159.6, 157.1, 146.7, 144.7, 138.9, 131.1, 130.6, 129.9, 129.4, 129.0, 128.7, 126.6, 125.0, 124.0, 122.2, 120.5, 115.6, 113.2, 111.5, 111.4, 98.0, 84.6, 78.6, 71.4, 68.8, 62.1, 56.1, 55.6, 29.2, 23.0; IR (film) ν_{max} 3288, 2976, 2934, 2835, 1373, 1250, 1117, 731 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₃₂H₃₄N₂O₈, 575.2393; found, 575.2368.

***N*-(4-Methoxybenzyl)-*N*-(6-((2*R*,3*R*,4*S*,5*R*)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2*H*-pyran-2-yloxy)naphthalen-2-yl)-4-methoxy-3-(3-methoxyphenyl)-benzamide (42c)**

Boron trifluoride etherate (10 μ L, 12 mg, 0.08 mmol) was added to **39** (77 mg, 0.15 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1.3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (214 mg, 0.59 mmol) in anhydrous CH₂Cl₂ (5.00 mL). After stirring at rt for 40 h, triethylamine (10 μ L) was added and the solvent was concentrated. The residue was partially purified via column chromatography (SiO₂, 1:1 EtOAc:Hexanes) to give **41c**, which was used without further purification (69 mg, 64%).

Carbonate **41c** (42 mg, 0.06 mmol) was added to MeOH (9.1 mL), CH₂Cl₂ (650 μ L), and triethylamine (910 μ L) and stirred for 18 h at rt. The solvent was concentrated and the residue purified via column chromatography (SiO₂, 2:1 EtOAc:Hexanes to EtOAc) to give **42c** as a colorless oil (27 mg, 66%, 42% over two steps): ¹H NMR (CDCl₃, 500 MHz) δ 7.58 (d, *J* = 8.8 Hz, 1H), 7.55 (d, *J* = 9.0 Hz, 1H), 7.48 (dd, *J* = 8.7, 2.2 Hz, 1H), 7.37 (d, *J* = 2.3 Hz, 1H), 7.35 (d, *J* = 2.0 Hz, 1H), 7.28 (d, *J* = 2.3 Hz, 1H), 7.25 (m, 2H), 7.14 (dd, *J* = 8.9, 2.4 Hz, 1H), 7.09 (t, *J* = 7.9 Hz, 1H), 7.04 (dd, *J* = 8.7, 2.1 Hz, 1H), 6.80 (m, 2H), 6.76 (ddd, *J* = 8.2, 2.5, 0.9 Hz, 1H), 6.73 (d, *J* = 8.7 Hz, 1H), 6.58 (m, 1H), 6.54 (brd, *J* = 7.7 Hz, 1H), 5.66 (d, *J* = 2.1 Hz, 1H), 5.14 (s, 2H), 4.25 (m, 1H), 4.22 (m, 1H), 3.77 (s, 3H), 3.70 (s, 3H), 3.63 (s, 3H), 3.61 (s, 3H), 3.38 (d, *J* = 9.2 Hz, 1H), 2.84 (brs, 1H), 2.71 (brs, 1H), 1.39 (s, 3H), 1.20 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.2, 159.2, 159.0, 157.6, 155.1, 140.1, 139.0, 132.9, 132.4, 130.5, 130.1 (2C), 129.5, 129.5, 129.4, 128.9, 128.3, 128.1, 127.1, 125.8, 122.1, 119.5, 114.7, 114.0, 113.2 (2C), 110.4, 109.9, 97.9, 94.6, 78.6, 71.5, 68.7, 62.1, 55.7, 55.4, 55.3, 53.9, 29.4, 22.9; IR (film) ν_{\max} 3420, 2932, 2835, 1601, 1506, 1394, 1387, 1248, 1178, 1117, 1026, 993, 910, 733 cm⁻¹; HRMS (ESI⁺) *m/z*: [M + H]⁺ calcd for C₄₁H₄₃NO₉, 694.3016; found, 694.3010.

***N*-(6-((2*R*,3*R*,4*S*,5*R*)-3,4-Dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2*H*-pyran-2-yloxy)naphthalen-2-yl)-4-methoxy-3-(3-methoxyphenyl)-benzamide (42d)**

Trifluoromethanesulfonic acid (130 μ L, 221 mg, 1.47 mmol) was added to **38** (198 mg, 0.33 mmol) in 1:1 CH₂Cl₂:TFA (1.48 mL) and the solution was stirred at rt for 2 h. The resulting solution was diluted with CH₂Cl₂ (100 mL), washed with saturated aqueous NaHCO₃ (3 \times 50 mL), saturated aqueous NaCl solution (2 \times 50 mL), dried (Na₂SO₄), filtered, and concentrated. The residue was partially purified via column chromatography (SiO₂, 1:1:1 Hexanes:EtOAc:CH₂Cl₂) to give **40** as a purple solid, which was used without further purification (28 mg, 22%).

Boron trifluoride etherate (4 μ L, 5 mg, 0.03 mmol) was added to **40** (28 mg, 0.07 mmol) and (3*aR*,4*S*,7*R*,7*aR*)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3*aH*-[1.3]dioxolo[4,5-*c*]pyran-4-yl 2,2,2-trichloroacetimidate (83 mg, 0.23 mmol) in anhydrous CH₂Cl₂ (1.85 mL). After stirring at rt for 40 h, triethylamine (10 μ L) was added and the solvent was concentrated. The residue was partially purified via column chromatography (SiO₂, 3:1:1 Hexanes:EtOAc:CH₂Cl₂) to provide **41d**, which was used without further purification (30 mg).

Carbonate **41d** was added to MeOH (10.0 mL), CH₂Cl₂ (1.0 mL), and triethylamine (1.0 mL) and stirred for 18 h at rt. The solvent was concentrated and the residue purified via column chromatography (SiO₂, 2:1 EtOAc:Hexanes, then EtOAc) to give **42d** as a colorless oil (12 mg, 6% in three steps): ¹H NMR (CDCl₃, 500 MHz) δ 8.28 (d, *J* = 1.9 Hz, 1H), 7.96 (dd, *J* = 8.5, 2.4 Hz, 1H), 7.90 (brs, 1H), 7.86 (d, *J* = 2.4 Hz, 1H), 7.75 (brs, 1H), 7.73 (brs, 1H), 7.55 (dd, *J* = 8.9, 2.2 Hz, 1H), 7.42 (d, *J* = 2.3 Hz, 1H), 7.38 (t, *J* = 8.0 Hz, 1H), 7.18 (dd, *J* = 8.9, 2.5 Hz, 1H), 7.15 (m, 1H), 7.11 (m, 1H), 7.09 (d, *J* = 8.7 Hz, 1H), 6.94 (ddd, *J* = 8.2, 2.5, 0.8 Hz, 1H), 5.69 (d, *J* = 2.1 Hz, 1H), 4.28 (dt, *J* = 9.2, 3.6 Hz, 1H), 4.25 (m, 1H), 3.91 (s, 3H),

3.87 (s, 3H), 3.62 (s, 3H), 3.39 (d, $J = 9.2$ Hz, 1H), 2.61 (d, $J = 2.5$ Hz, 1H), 2.56 (d, $J = 3.7$ Hz, 1H), 1.41 (s, 3H), 1.22 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 165.4, 159.6 (2C), 154.2, 139.1, 134.2, 131.8, 131.0, 129.9, 129.7, 129.4, 129.4, 128.6, 128.2, 127.4, 122.2, 120.9, 119.5, 117.3, 115.5, 113.2, 111.3, 110.1, 97.9, 84.7, 78.5, 71.6, 68.8, 62.1, 56.1, 55.6, 29.4, 22.9; IR (film) ν_{max} 3400, 2970, 2930, 2835, 1605, 1535, 1342, 1250, 1178, 1117, 1024, 995, 966, 908, 733 cm^{-1} ; HRMS (ESI⁺) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{33}\text{H}_{35}\text{NO}_8$, 574.2441; found, 574.2461.

Anti-Proliferation Assays

Cells were maintained in a 1:1 mixture of Advanced DMEM/F12 (Gibco) supplemented with non-essential amino acids, L-glutamine (2 mM), streptomycin (500 $\mu\text{g}/\text{mL}$), penicillin (100 units/mL), and 10% FBS. Cells were grown to confluence in a humidified atmosphere (37° C, 5% CO_2), seeded (2000/well, 100 μL) in 96-well plates, and allowed to attach overnight. Compound or GDA at varying concentrations in DMSO (1% DMSO final concentration) was added, and cells were returned to the incubator for 72 h. At 72 h, the number of viable cells was determined using an MTS/PMS cell proliferation kit (Promega) per the manufacturer's instructions. Cells incubated in 1% DMSO were used at 100% proliferation, and values were adjusted accordingly. IC_{50} values were calculated from separate experiments performed in triplicate using GraphPad Prism.

Western Blot Analyses

MCF-7 cells were cultured as described above and treated with various concentrations of drug, GDA in DMSO (1% DMSO final concentration), or vehicle (DMSO) for 24 h. Cells were harvested in cold PBS and lysed in RIPA lysis buffer containing 1 mM PMSF, 2 mM sodium orthovanadate, and protease inhibitors on ice for 1 h. Lysates were clarified at 14000g for 10 min at 4° C. Protein concentrations were determined using the Pierce BCA protein assay kit per the manufacturer's instructions. Equal amounts of protein (20 μg) were electrophoresed under reducing conditions, transferred to a nitrocellulose membrane, and immunoblotted with the corresponding specific antibodies. Membranes were incubated with an appropriate horseradish peroxidase-labeled secondary antibody, developed with a chemiluminescent substrate, and visualized.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The authors gratefully acknowledge support of this project by the NIH/NCI (CA120458) and the DOD Prostate Cancer Research Program (QH815179). The authors acknowledge Donna Lubbers for her preliminary studies toward the preparation of **14**, **17**, and **21**.

References

1. Powers MV, Workman P. In *Endocrine-Related Cancer* 2006;13:S125–S135.
2. Pratt WB, Toft DO. *Exp Biol Med* 2003;228:111–133.
3. Issacs JS, Xu W, Neckers L. *Cancer Cell* 2003;3:213–217. [PubMed: 12676580]
4. Terasawa K, Minami M, Minami YJ. *Biochem* 2005;137:443–447.
5. Buchner J. *Trends Biochem Sci* 1999;24:136–141. [PubMed: 10322418]
6. Picard D. *Cell Mol Life Sci* 2002;59:1640–1648. [PubMed: 12475174]
7. Yonehara M, Minami Y, Kawata Y, Nagai J, Yahara I. *J Biol Chem* 1996;271:2641–2645. [PubMed: 8576234]

8. Xiao L, Lu X, Ruden DM. *Mini-Reviews in Medicinal Chemistry* 2006;6:1137–1143. [PubMed: 17073714]
9. Zhao R, Houry WA. *Biochem Cell Biol* 2005;83:703–710. [PubMed: 1633321]
10. Neckers L, Ivy SP. *Curr Opin Oncol* 2003;15:419–424. [PubMed: 14624223]
11. Yu XM, Shen G, Neckers L, Blake H, Holzbeierlein J, Cronk B, Blagg BSJ. *J Am Chem Soc* 2005;127:12778–12779. [PubMed: 16159253]
12. Zhang H, Burrows F. *J Mol Med* 2004;82:488–499. [PubMed: 15168026]
13. Chiosis G, Vilenchik M, Kim J, Solit D. *Drug Discuss Today* 2004;9:881–888.
14. Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BSJ. *J Am Chem Soc* 2006;128:15529–15536. [PubMed: 17132020]
15. Toft DO. *Trends Endocrin Metab* 1998;9:238–243.
16. Walter S, Buchner J. *J Agnew Chem, Int Ed* 2002;41:1098–1113.
17. Blagg BSJ, Kerr TD. *Med Res Rev* 2006;26:310–338. [PubMed: 16385472]
18. Maloney A, Workman P. *Expert Opin Biol Ther* 2002;2:3–24. [PubMed: 11772336]
19. Workman P. *Cancer Letters* 2004;206:149–157. [PubMed: 15013520]
20. Sreedhar AS, Kalmar E, Csermely P, Shen YF. *FEBS Letters* 2004;562:11–15. [PubMed: 15069952]
21. Workman P. *Cold Spring Harbor Symposia on Quantitative Biology* 2005;70:499–515.
22. Lewis RJ, Tsai FT, Wigley DB. *BioEssays* 1996;18:661–671. [PubMed: 8760340]
23. Reece RJ, Maxwell A. *Crit Rev Biochem Mol Biol* 1991;26:335–375. [PubMed: 1657531]
24. Laurin P, Ferroud D, Schio L, Klich M, Dupuis-Hamelin C, Mauvais P, Lassaing P, Bonnefoy A, Musicki B. *Bioorg Med Chem Lett* 1999;9:2875–2880. [PubMed: 10522710]
25. Ali JA, Jackson AP, Howells AJ, Maxwell A. *Biochemistry* 1993;32:2717–2724. [PubMed: 8383523]
26. Holdgate GA, Tunncliffe A, Ward WHJ, Weston SA, Rosenbrock G, Barth PT, Taylor IWF, Paupit RA, Timms D. *Biochemistry* 1997;36:9663–9673. [PubMed: 9245398]
27. Lewis RJ, Singh OMP, Smith CV, Skarzyński T, Maxwell A, Wonacott AJ, Wigley DB. *EMBO J* 1996;15:1412–1420. [PubMed: 8635474]
28. Tsai FTF, Singh OMP, Skarzyński T, Wonacott AJ, Weston S, Tucker A, Paupit RA, Breeze AL, Poyser JP, O'Brien R, Ladbury JE, Wigley DB. *Proteins: Struct, Funct, Genet* 1997;28:41–52. [PubMed: 9144789]
29. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. *J Med Chem* 1999;42:260–266. [PubMed: 9925731]
30. Gobernado M, Canton E, Santos M. *Eur J Clin Microbiol* 1984;3:371. [PubMed: 6489329]
31. Schwartz GN, Teicher BA, Eder JP Jr, Korbut T, Holden SA, Ara G, Herman TS. *Cancer Chemother Pharmacol* 1993;32:455–462. [PubMed: 8258194]
32. Nordenberg J, Albukrek D, Hadar T, Fux A, Wasserman L, Novogrodsky A, Sidid Y. *Br J Cancer* 1992;65:183–188. [PubMed: 1739614]
33. Hombrouck C, Capmau M, Moreau N. *Cell Mol Biol* 1999;45:347–352. [PubMed: 10386791]
34. Marcu MG, Schulte TW, Neckers L. *J Natl Cancer Inst* 2000;92:242–248. [PubMed: 10655441]
35. Marcu MG, Chadli A, Bohouche I, Catelli B, Neckers LM. *J Biol Chem* 2001;276:37181–37186.
36. Allan RK, Mok D, Ward BK, Ratajczak T. *J Biol Chem* 2006;281:7161–7171. [PubMed: 16421106]
37. Burlison JA, Blagg BSJ. *Org Lett* 2006;8:4855–4858. [PubMed: 17020320]
38. Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J, Blagg BSJ. *J Org Chem* 2008;73:2130–2137. [PubMed: 18293999]
39. Shen G, Yu XM, Blagg BSJ. *Bioorg Med Chem Lett* 2004;14:5903–5906. [PubMed: 15501066]
40. Klaholz BP, Moras D. *Structure* 2002;10:1197–1204. [PubMed: 12220491]
41. Soti C, Vermes A, Haystead TAJ, Csermely P. *Eur J Biochem* 2003;270:2421–2428. [PubMed: 12755697]
42. Nabaei-Bidhendi G, Bannerjee NR. *J Indian Chem Soc* 1990;67:43–45.
43. Horvath RF, Chan TH. *J Org Chem* 1986;52:4489–4494.
44. Miyake M, Hanaoka Y, Fujimoto Y, Sato Y, Taketomo N, Yokota I, Yoshiyama Y. *Heterocycles* 1996;43:665–674.

45. Carreno MC, Garcia Ruano JL, Toledo MA, Urbano A. *Tetrahedron: Asymmetry* 1997;8:913–921.
46. Wang Y, Tan W, Li WZ, Li Y. *J Nat Prod* 2001;64:196–199. [PubMed: 11429999]
47. Ruenitz PC, Bagley JR, Nanavati NT. *J Med Chem* 1988;31:1471–1475. [PubMed: 3385736]
48. Milne JE, Buchwald SL. *J Am Chem Soc* 2004;126:13028–13032. [PubMed: 15469301]
49. Elliger CA. *Synth Commun* 1985;15:1315–1324.
50. Robinson AJ, Lim CY, He L, Ma P, Li HY. *J Org Chem* 2001;66:4141–4147. [PubMed: 11397145]
51. Toplak R, Svete J, Stanovnik B, Grdadolnik SG. *J Hetero Chem* 1999;36:225–235.
52. Hansen MM, Riggs JR. *Tetrahedron Lett* 1998;39:2705–2706.
53. Zymalkowski F, Tinapp P. *Justus Liebigs Ann Chem* 1966;699:98–106. [PubMed: 5986850]
54. Zhang H, Cai Q, Ma D. *J Org Chem* 2005;70:5164–5173. [PubMed: 15960520]
55. Ulbrich HK, Luxenburger A, Prech P, Eriksson EE, Soehnlein O, Rotzius P, Lindborn L, Dannhardt G. *J Med Chem* 2006;49:5988–5999. [PubMed: 17004713]
56. Jin Y, Zhou ZY, Tian W, Yu Q, Long YQ. *Bioorg Med Chem Lett* 2006;16:5864–5869. [PubMed: 16942876]
57. Akiyama T, Takesue Y, Kumegawa M, Nishimoto H, Ozaki S. *Bull Chem Soc Jpn* 1991;64:2266–2269.
58. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweiko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC. *J Med Chem* 2006;49:6819–6832. [PubMed: 17154512]
59. Ling KQ, Sayre LM. *J Am Chem Soc* 2006;127:4777–4784. [PubMed: 15796543]
60. Radanyi C, La Bras G, Messaoudi S, Couclier C, Peyrat JF, Brion JD, Marsaud V, Renoir JM, Alami M. *Bioorg Med Chem Lett* 2008;18:2495–2498. [PubMed: 18304811]
61. Le Bras G, Radanyi C, Peyrat JF, Brion JD, Alami M, Marsaud V, Stella B, Renoir JM. *J Med Chem* 2007;50:6189–6200. [PubMed: 17979263]
62. Faraoni R, Blanzat M, Kubicek S, Braun C, Schweizer WB, Gramlich V, Diederich F. *Org Biomol Chem* 2004;2:1962–1964. [PubMed: 15254618]
63. Nadin A, Lopez JMS, Owens AP, Howells DM, Talbot AC, Harrison T. *J Org Chem* 2003;68:2844–2852. [PubMed: 12662061]
64. Akritopoulou-Zanze I, Patel JR, Hartandi K, Brenneman J, Winn M, Pratt JK, Grynfarb M, Goos-Nisson A, von Geldern TW, Kym PR. *Bioorg Med Chem Lett* 2004;14:2079–2082. [PubMed: 15080982]
65. Klarmann E. *J Am Chem Soc* 1926;48:791–794.
66. Greig LM, Slawin AMZ, Smith MH, Philp D. *Tetrahedron* 2007;63:2391–2403.
67. Green K. *J Org Chem* 1991;56:4325–4326.




Figure 1.
Structure of novobiocin.




Figure 2.
Structures of **A4**, **DHN1**, **DHN2**, and **A4 dimer**.




Figure 3.
Complementarity of GTP and coumarin analogues.




Figure 4. Structure–activity relationships observed for the coumarin scaffold of novobiocin analogues exhibiting anti-proliferative activities.







Figure 5. Western blot analyses of Hsp90 client protein degradation assays against MCF-7 breast cancer cells. Concentrations (in μM) of **26g** (top), **26j** (middle), and **42d** (bottom) are indicated above each lane. GDA (geldanamycin, 500 nM) and DMSO were respectively employed as positive and negative controls.




Scheme 1.
Retrosynthesis of novobiocin analogues.

**Scheme 2.**


Syntheses of 4-substituted resorcinols. OEOM = OCH₂OEt.




Scheme 3.
Synthesis of 5-substituted resorcinol.




Scheme 4.
Syntheses of 2-substituted resorcinols.




Scheme 5.
Synthesis of 2-methoxy resorcinol and 2-ethyl resorcinol.




Scheme 6.
Preparation of 5-, 6-, and 8-modified novobiocin analogues.



Scheme 7.
Syntheses of 7-hydroxyquinolines.



Scheme 8.
Syntheses of 6-hydroxynaphthalenes.

**Scheme 9.**

Preparation of quinoline- and naphthalene-derived novobiocin analogues.

Table 1

Anti-proliferation activities of coumarin-derived novobiocin analogues.

Compound (IC ₅₀ , μ M)	R ¹	R ²	R ³	R ⁴	MCF-7	SKBr3	PC-3	LnCaP
26a	biaryl	H	OMe	Me	> 100 ^a	58.8 \pm 1.3	35.4	6.6
26b	biaryl	H	OPr	Me	> 100	> 100	5.6 \pm 5.7	3.0 \pm 0.6
26c	biaryl	H	O ^t Pr	Me	66.9 \pm 3.1	58.6 \pm 5.4	60.7 \pm 9.1	14.4 \pm 4.2
26d	biaryl	OMe	H	Me	82.8	55.7 \pm 6.9	11.3 \pm 2.0	2.0 \pm 0.8
26e	biaryl	H	H	Bn	> 100	> 100	> 100	49.7 \pm 25.0
26f	biaryl	H	H	Ph	> 100	17.3 \pm 3.4	> 100	1.0 \pm 0.1
26g	biaryl	H	H	OMe	9.0 \pm 5.4	13.9 \pm 1.2	2.3 \pm 2.9	1.1 \pm 0.1
26h	biaryl	H	H	Et	41.7 \pm 14.0	28.6 \pm 1.1	1.8 \pm 0.6	1.6 \pm 0.3
26i	2-indole	H	OMe	Me	24.4 \pm 1.2	25.1 \pm 7.7	20.2 \pm 9.8	10.5 \pm 0.3
26j	2-indole	H	OPr	Me	2.1 \pm 0.1	2.1 \pm 0.8	6.2 \pm 1.8	1.8 \pm 0.7
26k	2-indole	H	O ^t Pr	Me	20.0 \pm 1.0	20.7 \pm 0.4	11.9	11.4
26l	2-indole	OMe	H	Me	6.1 \pm 1.7	9.0 \pm 0.8	11.8 \pm 1.3	12.9 \pm 4.4
26m	2-indole	H	H	Bn	13.2 \pm 0.6	38.0 \pm 3.0	73.3 \pm 3.7	67.6 \pm 6.3
26n	2-indole	H	H	Ph	22.9 \pm 2.1	38.8 \pm 8.3	28.0 \pm 12.1	27.6 \pm 10.8
26o	2-indole	H	H	OMe	> 100	9.7 \pm 1.0	> 100	> 100
26p	2-indole	H	H	Et	4.3 \pm 2.5	4.3 \pm 3.4	> 100	> 100

^aValues represent mean \pm standard deviation for at least two separate experiments performed in triplicate.

Table 2
Anti-proliferation activities of quinoline- and naphthalene-containing novobiocin analogues.

Compound	R ¹	R ⁷	X	MCF-7	SkBr3	PC-3	LnCaP
42a	biaryl	4-OMe-Bn	N	> 100 ^a	> 100	> 100	> 100
42b	biaryl	H	N	13.1 ± 4.1	16.5 ± 6.2	17.6 ± 4.6	14.2 ± 0.4
42c	biaryl	4-OMe-Bn	CH	> 100	> 100	> 100	> 100
42d	biaryl	H	CH	46.4 ± 5.3	38.9 ± 2.4	10.9 ± 0.7	19.6 ± 1.6

^aValues represent mean ± standard deviation for at least two separate experiments performed in triplicate.